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ABSTRACT 
Anthracyclines remain widely prescribed and successful anticancer agents, despite 
serious side effects. Doxorubicin (DOX) is the most prominent anthracycline used to treat 
many cancers, including hematologic malignancies, soft-tissue sarcomas, cancers of the 
head and neck, and breast cancer. However, the clinical application of DOX is limited by 
the development of life-threatening cardiomyopathy and congestive heart failure. The main 
mechanisms of cardiotoxicity are thought to be mediated through the C-13 carbonyl and 
quinone ring structures in DOX. To improve the anticancer activity and reduce the 
cardiotoxic side effects of DOX, two synthetic analogs (GPX-150 and GPX-160) were 
developed and tested for in vitro and in vivo activity against a panel of soft tissue sarcoma 
cells. The analogs were further subjected to an array of tests to examine drug stability, 
transport properties, topoisomerase inhibitory activity and metabolism by cytochrome 
P450 enzymes. 
The two analogs were effective anticancer agents against an array of cancer cells. In 
particular, GPX-160 exhibited in vitro cytotoxicity against human soft tissue sarcoma 
(STS) cells that was similar to DOX. Importantly, GPX-160 functioned equally well 
against both DOX-sensitive and DOX-resistant sarcoma cell lines, suggesting that its 
structural modifications allowed it to resist P-glycoprotein mediated drug efflux. 
Moreover, in a murine xenograft model of human STS, both GPX-150 and GPX-160 
treatment resulted in significant decreases in both fibrosarcoma tumor volume and weight 
relative to the vehicle-treated controls. 
vii 
The stability of the DOX analogs in tissue culture media suggest that in the absence of 
drug metabolizing enzymes, GPX-150 (t1/2  = 55.9 hr) will persist approximately 8-fold 
longer than DOX (t1/2  = 6.8 hr) and 3-fold longer than GPX-160 (t1/2  = 20.7 hr). In vitro 
drug absorption studies across Caco-2 cell monolayers indicate that GPX-150 and GPX-
160 have higher permeability coefficients than DOX in both apical-to-basolateral and 
basolateral-to-apical directions. However, the transport of the analogs is not as heavily 
polarized in the basolateral-to-apical direction, as is seen with DOX. Both analogs also 
inhibited human topoisomerase IIα at low micromolar concentrations, supporting the 
possibility that they share a similar primary mechanism of action with DOX. Finally, 
human liver microsome metabolism of the two analogs showed that they were insensitive 
to aldo-keto reductase activity, which was expected based on the loss of the C-13 carbonyl 
and quinone structures. However, GPX-150 and GPX-160 remained sensitive to CYP2C8 
and CYP3A4 activity. 
Overall, these studies serve as an initial characterization of two DOX analogs that 
appear to hold great promise as a next generation of anthracyclines that overcome 
problems of drug resistance, while mitigating the cardiotoxicity that has limited the use of 
DOX. 
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CHAPTER ONE: INTRODUCTION  
1. Cancer 
Cancer is marked by the uncontrolled proliferation of genetically damaged cells that do 
not respond to the normal regulatory mechanisms employed in multicellular organisms. 
The uncontrolled proliferation of cancer cells interferes with the nutrient uptake of adjacent 
normal cells. With time, growing masses of cancer cells can crowd and outcompete healthy 
cells for resources and compromise vital tissue functions. 
Abnormal cells can become either benign or malignant tumors. Benign tumors are not 
cancerous as they grow slowly, are limited to a specific location, and rarely cause death. 
On the other hand, malignant tumors are eventually lethal as they undergo metastasis and 
often spread through lymph vessels or the bloodstream to distant parts of the body. 
Malignant tumors disrupt biological activities of normal cells, and if left untreated, can 
lead to death. 
Cancer is the second most common cause of death in the U.S, preceded only by heart 
disease. An estimated 1.7 million new cancer cases are presumed to be diagnosed in 2017 
and about 600,000 patients are expected to die of cancer1. Breast carcinomas and prostate 
cancers are the most common cancers for females and males, respectively. Lung cancers 
are the leading cause of death for both women and men. 
Cancers are classified by the tissues affected. The majority of cancerous tumors are 
carcinomas, in which tumors originated from epithelial tissue, such as skin, glands, and the 
lining of most internal organs. Leukemias are cancers of the bone marrow where leukocytes 
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are produced. Similarly, lymphomas are cancers in which lymphocytes uncontrollably 
proliferate in the lymph nodes. Tumors originating in connective tissue are called 
sarcomas. Compared to the other cancer types, sarcomas are understudied due to their low 
rate of occurrence. 
2. Soft Tissue Sarcomas 
Soft tissue sarcomas (STS) are a rare type of cancer derived from transformed cells of 
mesenchymal origin. STS represent 1% of all adult cancers and can originate in many types 
of tissue including adipose tissue (liposarcoma), skeletal muscle (rhabdomyosarcoma), 
smooth muscle (leiomyosarcoma), and blood and lymph nodes (angiosarcoma)2. The 
identification of STS relies on clinical examination, imaging, and histologic analysis3. 
There are more than 50 subtypes of STS4. Most sarcomas occur in the extremities account 
for 60-70% (about 40% lower and 20% upper) of STS3. 
Surgery is the typical treatment for local control of extremity STS followed by radiation 
and chemotherapy. The 5-year local control rates in patients with adjuvant radiotherapy 
improved by 18% compared with those treated with surgery alone5. Adjuvant doxorubicin-
based chemotherapy also improves overall survival for metastatic STS as it reduces the 
risk of local recurrence by 27% with an absolute benefit of 6% at 10 years. Even though 
systematic control by chemotherapy can be useful, the overall outcome of STS treatment 
is unsatisfactory and survival rates have remained stagnant for more than 50 years6. In 
addition, the use of adjuvant chemotherapy is limited and controversial. Doxorubicin, the 
single most active chemotherapeutic agent for STS, shows a 30% overall response rate but 
causes cardiotoxicity as a side effect, which limits its use6. Therefore, new 
chemotherapeutic regimens are required for treatment of STS. 
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3. History of Doxorubicin 
Doxorubicin (DOX, Adriamycin®, 14-hydroxydaunorubicin, NSC-123,127) is one of 
the anthracycline-based antitumor agents considered as a mainstay chemotherapeutic since 
its approval for use in 19747. The parent compound of DOX is daunorubicin (DNR). DNR 
was first isolated in the early 1960’s from pigment-releasing Streptomyces peucetius var. 
caesius strains, followed by the discovery of DOX8. Early on, DNR was found to be potent 
in treating leukemias and lymphomas9. Later, DOX was found to be a better anticancer 
agent than DNR for treating a variety of cancers, including leukemias, Hodgkin’s and non-
Hodgkin’s lymphomas, and solid tumors of the breast, lung, ovaries, bladder, thyroid, and 
stomach10. DOX was also found to be effective in the treatment of multiple myeloma and 
STS, including Kaposi’s sarcoma11. 
Since the 1960s, hundreds of DOX analogs have been synthesized and investigated for 
anticancer activity12, although few have progressed to common clinical use. Despite the 
potential for significant adverse effects, DOX remains one of the most prescribed 
chemotherapeutic agents. It is considered by the World Health Organization to be so 
important that it is on their “List of Essential Medicines” that should be available in a health 
care system13. 
4.  Structures of Doxorubicin and Early Analogs 
Structurally, anthracyclines consist of a daunosamine sugar moiety linked to a 
tetracycline with neighboring quinone and hydroquinone groups in the center, a methoxy 
group at C-4, and a short side chain with a carbonyl group at C-13 (see Figure 1). The 
daunosamine sugar is composed of a 3-amino-2, 3, 6-trideoxy-L-fucosyl substituent, and 
is attached at C-7 of the tetracyclic ring. The differences between DNR and DOX exist at 
4 
 
 
the short side chain next to the C-13 carbonyl group attached to the A ring. DNR contains 
a methyl group that is hydroxylated in DOX. Idarubicin (IDA, 4-demethoxydaunorubicin) 
and epirubicin (EPI, 4’-epidoxorubicin) are first generation anthracycline derivatives of 
DNR and DOX, respectively. IDA represents DNR without a C-4 methoxy group on ring 
D. EPI resembles DOX, but has an axial-to-equatorial epimerization of hydroxyl group in 
the sugar moiety, thus forming an acosamine instead of daunosamine sugar. Due to the 
very similar structures, these compounds share similar mechanisms of action for their 
antitumor effects. 
 
Figure 1.1 Structures of early anthracyclines 
5 Mechanisms of Action of Doxorubicin 
The antitumor activity of DOX has been investigated for several decades since its 
discovery. The three most widely accepted mechanisms of action are as follows: (1) DNA 
intercalation and inhibition of topoisomerase activity14, (2) production of reactive oxygen 
and nitrogen species (RONS) yielding DNA damage and/or lipid peroxidation15, (3) and 
 
5 
 
 
formation of DNA adducts and/or crosslinking to proteins to interrupt replication and 
transcription16. 
5.1 DNA Intercalation and Topoisomerase II Poisons 
DOX initially intercalates between DNA base pairs to form a stable DOX-DNA-
topoisomerase II, ternary complex. As a result, both DNA strands are cut but not resealed, 
ultimately leading to extensive DNA damage. The structure of DOX explains how it 
intercalates DNA and forms this stable complex. For instance, the planar ring system of 
DOX drives DNA intercalation through numerous hydrophobic interactions as the B and 
C ring overlaps adjacent base pairs, and the D ring passes through the intercalation site (see 
Figure 2). The non-intercalating groups such as the sugar moiety and ring A, stabilize the 
cleavable complex17. The sugar moiety associates with the minor groove of DNA and 
topoisomerase complex to deform the DNA structure18,19. It has been demonstrated that the 
removal or modification of amino- substituents at the C-3’ position in the sugar and/or 
methoxy group at C-4 in the D ring increases the topoisomerase II (Top2) poisoning, 
thereby increasing the overall anticancer activity20–22. 
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Several studies have classified DOX as a Top2 poison23,24. DNA topoisomerases are 
ubiquitous enzymes that play a crucial role in regulating genomic integrity. These enzymes 
supervise the topology of cellular DNA by catalyzing the unwinding of DNA supercoiling 
through DNA strand passage and re-ligation without altering its sequence and structure. 
Topoisomerases regulate DNA replication, recombination, repair, transcription, and 
apoptotic DNA degradation25. Topoisomerases are divided into two subfamilies based on 
their chemical structure: topoisomerase I (type 1) and II (type 2). Topoisomerase I is a 
monomer, which transiently cleaves a single-strand of DNA duplex to unwind the 
supercoiled-DNA. In contrast, topoisomerase II is an oligomer that transiently cleaves both 
Figure 1.2. Stereoscopic skeletal sketch of the DOX-DNA complexes (left) and 
stacking interaction between DOX and the adjacent base pairs in a perpendicular 
view (right). DOX (dark bonds) intercalates between the terminal two base pairs 
of DNA as the sugar moiety penetrates through the helix. The sugar residue and 
ring A reside outside of the intercalation site and stabilize the ternary complex. 
The N-3 amino group of the sugar lies in the minor groove, and can also form a 
covalent bond with the guanine base of DNA (modified from Zhang et al., 1993). 
A 
B 
C 
D 
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strands of the DNA duplex, relaxing the supercoiled-DNA26. Six different topoisomerases 
exist in human cells: 1A (Top3α and β), 1B (Top1 and Top1mt), and 2a (Top2α and β)27. 
Top2α is a nuclear isozyme composed of a dimer of two identical subunits that requires 
ATP hydrolysis (Figure 3)28. The enzyme appears in fast-growing cancer cells, and is a 
primary molecular target for DOX29. DOX interaction with Top2-DNA covalent 
complexes induces DNA damage, including double-strand breaks (DSBs). DSBs in 
chromosomal DNA induced by DOX are stabilized by the proteosome31,32. In response to 
DSBs, the histone H2A variant γ-H2AX is phosphorylated and initiates a signaling cascade 
that alerts the cell to DNA damage, leading to growth arrest in G1 and G2 phases, and 
apoptosis33,34. 
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Figure 1.3. DOX inhibits topoisomerase II (Top2) at several sites in the reaction 
cycle: I. DOX can block Top2 binding to the G segment of DNA (blue). II. DOX can 
also inhibit the advancement of the DNA T segment (red) into the central hole before 
ATP binds to the ATPase domain (yellow). III. DOX interferes with release of the 
T segment from the A and A’ domains (green) at the bottom of the dimer. IV. DOX 
interrupts ATP hydrolysis and regeneration of the starting state (modified from 
Nitiss, 2009). 
DOX 
I 
DOX 
III 
III 
DOX 
IV 
DOX 
II 
II 
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5.2 Production of Free Radicals and Reactive Oxygen Species (ROS) 
The quinone moiety in ring C of DOX can undergo a one-electron reduction catalyzed 
by flavin oxido reductases35, forming a semiquinone that decomposes to the parent 
quinone and reduces oxygen to reactive species such as hydrogen peroxide (H2O2), 
superoxide anion (·O2-)36, and ultimately hydroxyl radical (·OH) (Figure 4). In a 
biological environment, ·OH can interact with cellular constituents, creating adducts 
of cellular DNA, peroxidizing lipids, or oxidizing tryptophan-, tyrosine-, and thiol-
Figure 1.4. The production of reactive oxygen species (ROS) and free 
radicals from doxorubicin by one-electron reduction catalyzed by oxido-
reductases.  
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containing functional groups in proteins and enzymes. Ultimately, these events 
disrupt function and lead to cell death37.  
DOX decomposition can create RONS through other routes as well. Reductive 
deglycosylation of DOX to a 7-deoxyaglycone is generated during the one-electron 
reduction cycle as the semiquinone may also oxidize the bond between the A ring and sugar 
moiety38. These aglycone products can readily permeate cells and organelles because of 
their increased lipid solubility to produce intracellular RONS39. RONS can also oxidize 
signaling molecules that modulate the activity of kinases or transcription factors, disrupting 
the cell cycle and stimulating apoptosis40–43. 
Free radical generation can also be mediated by metals, particularly iron. DOX forms 
an iron coordination complex with dinucleotides44,45. Several studies have shown that the 
presence of the C-11 hydroxyl group is fundamental for iron binding and thiol-dependent 
oxygen consumption. DOX can complex with iron to directly reduce Fe (III) to Fe (II), 
which then reacts with molecular oxygen or hydrogen peroxide to sponsor DNA adduct 
formation46. This iron-DOX complex mediates oxidative damage and is considered one of 
the primary mechanisms of DOX anticancer action. 
5.3 DNA Adducts and Cross-linking 
In addition to creating DOX-DNA-Top2 complexes that disrupt DNA replication 
through stabilized double strand breaks, DOX can also directly form covalent DNA adducts 
that lead to cytostatic effects47,48. These direct DNA-adducts were first described by Sinha 
and Chignell in 197949. Formaldehyde in the cell creates a methylene group at the 3’ amino 
moiety on the sugar of DOX and binds to the N-2 residue of guanine in the DNA (Figure 
5). This reactive intermediate attacks the 2-amino group of deoxyguanosine residues in the 
DNA via Schiff base chemistry to create the DOX-DNA adduct16,50,51. Reaction rates can 
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be increased through catalysis by xanthine oxidase and NADPH52. Cullinane and Philips 
discovered that DOX can create adducts with both single and double stranded DNA and 
hypothesized that this occurred through a quinone methide intermediate12. Taatjes and 
Koch et al. suggested that DOX iron-catalyzed free radical reactions induce formaldehyde 
production from cellular carbon sources such as lipids and spermine in an oxidative stress 
environment, thus stimulating DOX-DNA adduct formation53,54. 
 
DNA cross-linkage is proposed to occur in a series of steps. Step 1 involves the 
interaction of DOX with the binding site of DNA, which yields the drug-DNA complex. 
In step 2, formaldehyde released from carbon sources via iron-catalyzed free radical 
reactions interacts to generate a covalent complex between the amine group on the DOX 
Figure 1.5. Structure of doxorubicin showing its covalent and non-
covalent bonding position to the c- and n-strands of DNA. Rings B, C, and 
D can intercalate in the minor groove of DNA. DNA-adducts are mediated 
through N-2 guanine nucleoside (blue) of DNA in either strand. The non-
covalent strand form hydrogen bonds with the hydroxyl group at ring A of 
DOX. The covalent linkage between the amino group of DOX and c-strand 
guanine N-2 derives from direct reaction with formaldehyde. The aminal 
(N-C-N) bond between N-3 amino group of guanine and daunosamine sugar 
forms DNA covalent cross linkages at 5’-GC-3’ sites. 
2 
A B C D 
1 
2 
1 
3’ 
5’ 
3
’ 
5’ 
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sugar and the N-2 amine group on the guanine base of the c-strand. Meanwhile, the N-3 
amine group in the guanine base of the DNA n-strand hydrogen bonds with the hydroxy 
group on ring A of DOX. Lastly, in step 3, formaldehyde produces the cross-linked ternary 
complex55. This primarily occurs between the daunosamine sugar and the N-2 amino group 
of guanine via an aminal (N-C-N) bond49,55,56, predominantly cross-linking at 5’-GC-3’ 
sites in DNA12. 
The concentration of formaldehyde is often higher in cancer cells than in normal cells57, 
thus DOX-DNA cross-linkage occurs more readily in cancer cells. As well, novel DOX 
analogs that more readily conjugate to formaldehyde should produce significantly 
enhanced rates of DNA adducts. A number of these analogs have been developed such as 
doxazolidine, doxoform, and doxaliform. DNA-drug adducts formed by these compounds 
and formaldehyde exhibited increased cytotoxicity in comparison to DOX, and they were 
less susceptible to drug-efflux based drug resistance58,59. The structure of DNA adducts is 
well supported by mass spectrometry16,50, 2D NMR51, and X-ray crystallography60. 
6. Mechanisms of Cardiotoxicity 
Although DOX is one of the most successful chemotherapeutic compounds, its clinical 
use is restricted by selective myocardial dysfunction, and dose-dependent reversible and 
irreversible cardiotoxicity60,61,62,63,64. This can result in pericarditis, arrhythmias, and left 
ventricular dysfunction65,66. The decreased left ventricular ejection fraction (LVEF) 
eventually leads to congestive heart failure (CHF)67. A decrease in LVEF and 
asymptomatic abnormalities may occur in patients at cumulative doses of DOX as low as 
300 mg/m2. The characterization of dose-induced cardiomyopathy is seen as a flattening 
of the T-wave, increased Q-T interval, reduced R-wave amplitude, atrial flutter, and 
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premature atrial and ventricular beats68,69. LVEF dysfunction results in a decrease in both 
systolic and diastolic function, with a substantial increase in left ventricular end-diastolic 
pressure70. At cumulative doses of 240 mg/m2 of DOX, significant histopathologic changes 
can also be seen in endomyocardial biopsy specimens, including loss of myofibrils, 
alteration to the sarcoplasmic reticulum, and increased vacuoles in the cytoplasm 
18,34,40,54,55,58,59. 
Cardiotoxicity can be categorized into three distinctive types: acute/subacute, early, 
and late-onset chronic progressive cardiotoxicity. Acute/subacute cardiotoxicity occurs 
within a week of DOX treatment, and explains observed transient arrhythmias72,73,74,75. In 
contrast, both early- and late-onset cardiotoxicity are categorized by a dose-induced, 
progressive reduction in LVEF with either symptomatic or asymptomatic cardiac 
abnormalities76,77. Early-onset cardiotoxicity occurs within a year of treatment, while late-
onset chronic cardiotoxicity may develop between 4 and 15 years after treatment has 
ended.78 
A number of investigations have studied the pathophysiology of DOX-induced 
cardiomyopathy. However, the molecular mechanisms still remain debatable and are 
incompletely understood. The main proposed mechanisms of cardiotoxicity are RONS 
overproduction by single electron reduction reactions39,79–82, and the reduction of the DOX 
C-13 carbonyl group to an alcohol to generate a toxic metabolite, doxorubicinol (DOXol) 
(Figure 6)81-86. 
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6.1 DOX-induced RONS Mediated Cardiotoxicity 
ROS can be generated via two significant molecular mechanisms: an enzymatic 
pathway triggered by several oxidoreductases via one-electron reduction, and an enzyme-
free pathway induced by anthracycline-iron complexes. In the first pathway, 
oxidoreductases catalyze reduction of the quinone moiety of the central anthracycline ring 
into a radical semiquinone. The semiquinone reduces oxygen to create superoxide anion 
Figure 1.6. Doxorubicin-induced mechanisms of cardiotoxicity via 1 
electron and 2 electron pathways. The 1 electron reduction pathway explains 
the production of reactive oxygen and nitrogen species (RONS). The two 
electrons reduction pathway leads to production of the secondary alcohol 
metabolite, doxorubicinol (DOXol).  
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and hydrogen peroxide, and regenerate the parent quinone. This pathway occurs in 
mitochondria by NADPH dependent ubiquinone oxidoreductase39,79,87–92, in microsomes 
via NADPH-cytochrome P450 or NADPH-cytochrome b5 reductases
88,93,94, and in the 
cytosol by xanthine dehydrogenase and nitric oxide synthases36,52,95–97. 
On the other hand, increased RONS formation can also be induced by anthracycline-
iron complexes. In the presence of oxygen, anthracycline binds to free Fe (III), becoming 
a drug-metal coordination complex. The complex generates superoxide anion and H2O2 as 
it alternates redox interaction between Fe (II) and Fe (III). DOX also associates with both 
hemoglobin98 and myoglobin, those can interact with iron98–103 or copper104–106, to generate 
metal complexes that can form free radical species by spontaneous oxidation in solution. 
The presence and amount of the respective oxidoreductases in specific cell types determine 
the source and amount of free radical formation, and where it occurs within the cell69. 
DOX-stimulated RONS production in cardiomyocytes causes mitochondrial damage 
that leads to apoptotic cell death through activation of caspase pathways107–109. The 
aglyconic form of DOX can also intercalate into mitochondrial membranes due to its high 
lipophilicity, and create even more RONS as it directs more electrons towards oxygen in 
single electron transfer reactions. In addition, DOX can generate peroxynitrite (ONOO-) as 
a result of excess production of superoxide anion and nitric oxide (NO) from 
overexpression of the inducible isoform of NO synthase (iNOS)110–113. Eventually, ONOO- 
can cause lipid peroxidation, protein nitrosylation, DNA strand breaks, and damage to a 
variety of cellular macromolecules. Overall, this futile oxidative and nitrosative stress lead 
cardiac dysfunction, mitochondrial damage69,114–118, energy imbalance116,119, and 
apoptosis17,108,120. 
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Cardiomyoctes are acutely susceptible to RONS, since they lack sufficient levels of 
detoxifying enzymes such as superoxide dismutase, catalase, and gluthathione peroxidase, 
to respond to the added oxidative stress elicited by DOX treatment121–123. The high 
metabolic activity in heart tissue also causes cardiac failure124. Additionally, DOX  
inactivates RONS detoxifying enzymes, thus increasing the likelihood of anthracycline-
induced cardiomyopathy.122,125 
6.2 DOX-induced Doxorubicinol Mediated Cardiotoxicity 
Doxorubicinol (DOXol) is a major metabolite of DOX that accumulates in 
cardiomyocytes, where it is produced by mitochondrial aldo-keto reductases (AKR) that 
reduce the C-13 carbonyl group to a secondary C-13 alcohol83. DOXol contributes to the 
delocalization and swelling of mitochondrial matrix of cardiomyocytes126,127,128. DOXol 
causes significant disruption to mitochondrial metabolism leading to declines in 
myocardial ATP, lactate, and phosphocreatine concentrations. Ultimately, this disrupts 
both oxidative and glycolytic metabolic pathways, causing severe cardiomyopathy129,130. 
DOXol seems more effective than DOX at blocking the Ca2+-Mg2+ ATPase of 
sarcoplasmic reticulum, the F0-F1 proton pump of mitochondria, and the Na
+-K+ ATPase 
and Na+-Ca2+ exchangers of the sarcolemma131. DOXol is also better than DOX at 
inhibiting spontaneous or caffeine-triggered Ca2+-release from the sarcoplasmic 
reticulum132. In vivo studies in rabbits suggest DOXol induces LVEF dysfunction and 
interruption of the ryanodine receptor associated with the Ca2+ release channel of the 
sarcoplasmic reticulum, whereas less LVEF shortening was found with treatment using C-
13 deoxy-DOX133. DOXol also modifies the aconitase/IRP-1 complex to a “null protein” 
that is devoid of aconitase and RNA binding activity by causing oxidative damage to 
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cysteine residues required to reconfigure an essential Fe-S cluster134–136. The inactivated 
aconitase/IRP-1 complex is incapable of sensing iron and fails to trigger iron uptake or 
sequestration, which consequence inactivates regulatory and metabolic pathways in the 
cardiomyocyte15. Ultimately this imbalance in iron homeostasis negatively impacts the 
heart systolic/diastolic cycle86. 
7. Prevention of Cardiotoxicity 
The effective use of DOX as an antineoplastic agent relies on the tissue concentration 
of drug and/or the total systemic exposure over time, rather than the peak plasma 
concentration146. Thus some of the problems encountered with acute or early DOX-induced 
cardiotoxicity can be avoided by altering the schedule of administration. Instead of a single 
bolus of drug by intravenous (IV) injection every 3 weeks, IV delivery of DOX over a 
period of 48-96 hours and lower weekly doses have been shown to reduce CHF rates46,147–
150. Regular monitoring for any clinical signs of cardiotoxicity by physical examination, x-
rays, echocardiogram, electrocardiogram (EKG), endomyocardial biopsy, and radionuclide 
angiography before, during, and after DOX chemotherapy is necessary to avoid severe 
CHF and morbidity. Physical examination by itself can detect more than 50% of early and 
reversible DOX-dependent CHF.152–154 
8.  Anthracycline Analogs 
The cardiotoxicity encountered with DOX is inherent to its chemical structure. For 
decades, DOX analogs have been explored to reduce the required drug dose to achieve a 
therapeutic response, and to reduce cardiotoxic side effects and drug resistance. Some of 
these DOX analogs are discussed below. 
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8.1 Epirubicin 
Epirubicin (4’-epidoxorubicin, EPI) is 
synthesized from DOX by epimerization of a 
hydroxyl group in the daunosamine sugar 
(Figure 7). This minor positional change 
discriminates the physicochemical and 
pharmacokinetic properties of EPI from DOX. 
EPI is more lipophilic, has weaker base characteristics, and a shorter half-life than 
DOX137,138. The rapid overall body clearance of EPI is due to β-glucuronidation by liver 
UDP-glucuronosyl transferase 2B7139, which diminishes its overall dose-induced 
cardiotoxicity140. EPI also undergoes limited one-electron reduction that predominantly 
occurs in cytoplasmic acid organelles, rather than the mitochondria141. Like DOX, AKR 
converts EPI to epirubicinol (EPIol) by limited two-electron reduction67,142,143. Several 
clinical studies have shown that EPI treatment does not produce as much of the toxic 
secondary alcohol in cardiac tissue149,150. CHF is not encountered with EPI at a single-dose 
level of 900-1000 mg/m2, which is 1.5 times higher than the dose limit for DOX141,144. In 
a study of breast cancer patients co-treated with 5-fluorouracil, cyclophosphamide, and EPI 
(90 mg/m2), followed by radiation therapy, patients did not show sign of symptomatic CHF 
in the first year of treatment145. Moreover, EPI-taxane combination therapy allowed a 
cumulative dose of EPI that was almost twice as high as that recommended for DOX146. 
However, minor LVEF was identified following cumulative EPI doses of 360-450 mg/m2. 
EPI is still reduced to EPIol and the minor formation of RONS can harm cardiomyocytes 
and decrease cardiac function147. 
Figure 1.7. The structure of 
epirubicin. 
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8.2 Idarubicin 
Idarubicin (4-demethoxydaunorubicin, 
IDA) is a DNR derivative that lacks a 
methoxy group at position 4 (Figure 8). Like 
DOX and other anthracyclines, IDA is a DNA 
intercalating agent that interrupts 
topoisomerase II function and DNA 
replication14. IDA has a higher lipophilicity than DNR, which results in an improved rate 
of cellular uptake21, a longer half-life, and increased ability to cross the blood-brain 
barrier148. IDA is another key component of chemotherapy regimens, and is potentially 
superior to DNR in treatment of acute myeloid leukemia (AML)149,150 and acute 
lymphocytic leukemia (ALL)151. Whereas DNR and DOX must be administered IV, IDA 
shows good oral bioavailability, although no benefit between oral and IV administration 
was observed for acute leukemia patients22. In randomized treatment trials, IDA showed 
less cardiotoxicity than DNR152. The increased drug effectiveness and prolonged survival 
in AML treatment makes IDA a better therapeutic than the parent DNR compound. 
However, in AML patients receiving a cumulative dose of 290 mg/m2, decreased LVEF 
and cardiomyopathy was observed21. Lastly, although IDA shows great potency in 
leukemia treatment, it appears to be less effective than DOX in treatment of metastatic 
breast cancer, and it still induces dose-dependent cardiotoxicity to those patients.153,154 
 
Figure 1.8. The structure of 
idarubicin. 
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8.3 Dissaccharide Anthracyclines 
A third generation of anthracycline analogs, 
Sabarubicin (MEN-10755) and morpholinyl- 
derivatives such as nemorubicin (PNU-152243A), are 
now being investigated to satisfy the need to have both 
anticancer effectiveness and reduced dose-induced 
cardiotoxicity (Figure 9). Both of these compounds are 
designed to investigate the role of the C-3 amino group 
of the daunosamine sugar to disrupt type-II 
topoisomerase activity through DNA cleavage and 
stabilization of the drug-DNA-topoisomerase 
complex.155-157 
Sabarubicin is known to be a leading disaccharide 
analog that is reported to have a better antitumor efficacy than DOX. Structurally, 
sabarubicin contains a 2,6-dideoxy-L-fucose between the algycone and sugar moieties with 
an elimination of the methoxy substituent at C-4 in the aglycone. Sabarubicin exhibits an 
increased spectrum of antiproliferative activity in human tumor xenografts158, improved 
anti-topoisomerase II action159, and reduced cardiomyopathy when compared to DOX160. 
The drug half-life of sabarubicin is 50% shorter than DOX and its cellular uptake and tissue 
accumulation are slower161. Several in vivo studies report reduced conversion of 
sabarubicin to its toxic secondary alcohol metabolite (sabarubicinol, MEN-10755ol), hence 
lowering its cardiotoxic potential135,160. In addition, the alcohol metabolite of sabarubicin 
is less reactive than DOXol toward the [Fe-S] cluster of cytoplasmic aconitase/IRP-1, 
 
 
 
Figure 1.9. The 
structures of sabarubicin 
and nemorubicin. 
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which is involved in mediating anthracycline-induced cardiotoxicity162. In a phase I clinical 
trial, sabarubicin still caused myelosuppresion, but the overall cumulative cardiotoxicity 
was mild, and only two patients showed decreased LVEF163. Furthermore, a phase II study 
of sabarubicin showed no CHF, although cardiotoxicity was observed in clinical trials in 
patients with regionally advanced or metastatic platinum/taxane resistant ovarian cancer164. 
Another disaccharide derivative that is being explored for clinical use is nemorubicin 
(3’-deamino-3’ [2”-(S)-methoxy-4-morpholinyl] doxorubicin; MMDX), which is a DOX 
derivative that retains a methoxymorpholinyl group at C-3 of the daunosamine sugar. Phase 
I and II clinical trials show promising results for the intrahepatic artery delivery of MMDX 
to treat hepatocellular carcinoma165–167. MMDX also shows encouraging efficacy against 
multidrug-resistant tumor cells in vitro and in vivo168,169. While minor damage to cardiac 
tissue was found by histological examination, in vivo studies of MMDX treatment at 
optimal therapeutic doses did not result in abnormal EKG170. In both animal and human 
clinical studies, MMDX appears to be 50-130 times more effective than DOX168,171. 
However, MMDX is only 2-10 fold more potent than DOX against adenocarcinomas (i.e 
ovarian and lung tumors) and hemocytoblasts in in vitro studies170,172. The increased anti-
tumor activity may be due to the biotransformation of MMDX that leads to more cytotoxic 
metabolites (MMDX N-oxide, PNU-159696, and PNU-159682)165,167. 
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8.4 C-13 Deoxy Anthracyclines 
Since the carbonyl group at C-13 and/or in the 
quinone moiety has the notorious impact of causing 
anthracycline-induced cardiomyopathy, novel 
compounds lacking these structures have been 
developed. GPX-150 (5-imino 13-
deoxydoxorubicin; DIDOX) is one such compound. 
In GPX-150 the C-13 carbonyl has been removed, 
and the quinone carbonyl has been replaced with nitrogen to generate an iminoquinone. 
This structure is less capable of generating ROS and cardiotoxic alcohols (Figure 10). 
Experimentally, GPX-150 is a poor substrate for carbonyl reductase173, likely due to the 
absence of C-13 carbonyl group and quinone moiety. Holstein et al. demonstrated in a 
phase I dose escalation study (as high as 265 mg/m2) that GPX-150 did not elicit acute 
cardiomyopathy among patients with advanced solid tumors174. In fact, GPX-150 treatment 
produced no clinically significant harm to cardiac function, even in patients with prior 
anthracycline history and minor LVEF shortening174. Unlike other anthracyclines, GPX-
150 treatment does not cause common patient side effects such as mucositis, stomatitis, or 
hand-foot syndrome. Further, a recent phase II study of GPX-150 for treatment of advanced 
and/or metastatic malignant STS patients revealed that this novel analog was well tolerated 
by patients with different sarcoma subtypes175. Furthermore, no irreversible cardiotoxicity 
was found and the toxicity profile that did result from the drug treatment appears to be 
manageable175. 
 
Figure 1.10. The structure of 
C-13 deoxy anthracycline, 
GPX-150. 
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8.5 Cancer-Targeted Formulations 
In an attempt to overcome the therapy-limiting toxicity of conventional anthracyclines 
and to restrict anthracycline uptake into heart tissue, new pharmacological approaches have 
been developed. One innovative approach is a liposomal formulation that shows promising 
drug carrier technology to increase the therapeutic profile of DOX176,177. Liposomal 
systems allow easy drug-delivery from the circulation into tumor tissue, in which cells are 
not as tightly joined as cells in normal tissues202. However, the application of liposome-
encapsulated DOX is limited due to its short half-life in plasma and the formation of 
cardiotoxic metabolites179. 
A number of liposomal DOX formulations that incorporate polymers such as 
polyethylene glycol (PEG), ganglioside, and cerebroside sulfate have been shown to 
actively target tumors and prolong serum half-life180. Pegylated-liposomal DOX (DOXil) 
is an FDA-approved formulation that resists drug uptake by the reticuloendothelial system 
(RES), improving its plasma half-life up to 4 days181. Also, DOXil remains encapsulated 
until it has reached the tumor cells182,183. Despite the promising effects of DOXil, it can 
still cause hand-foot syndrome (HFS or palmar-plantar erythrodyesthesia), which is 
characterized by skin eruptions on the palms of the hands and soles of the feet184. 
8.6 Cardioprotective Agents 
Dexrazoxane (DZR, ICRF-
187, Cardioxane®) is the only drug 
that has been approved in the U.S, 
Canada, and Europe to protect 
against anthracycline-mediated 
Figure 1.11. The structures of dexrazoxane 
and its metal ion chelating hydrolysis product, 
ADR-925. 
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cardiotoxicity185,186. DZR is a bisdioxopiperazine and an enantiomer of razoxane, which 
was initially discovered as a chemotherapeutic agent. DZR quickly penetrates the cell 
membrane and is enzymatically hydrolyzed to produce ADR-925, an active metal chelator 
(Figure 11). ADR-925 ligates free iron and inhibits the generation of ROS by 
anthracycline-Fe complexes. ADR-925 also readily dissociates Fe (III) from the 
anthracycline-iron complexes. The cardioprotective mechanism of DZR is not fully 
understood, but it is proposed to be a better chelator of Fe (III) than DOX, and thus blocks 
iron-driven RONS production187. DZR also disrupts Top2 activity like DOX, although 
through a distinct mechanism. DZR stabilizes the ATP-bound closed-clamp configuration 
of Top2 through antagonist interaction with the Top2-DNA complexes188,189,190. 
In the U.S, DZR is labeled as an orphan drug for treatment of metastatic breast cancer 
in patients who have already received 300 mg/m2 DOX. The results of two Phase III clinical 
studies reported that concomitant DZR treatment with fluorouracil, doxorubicin, and 
cyclophosphamide (collectively referred to as “FAC”) in advanced breast cancer produced 
significant cardioprotection191. Also, Swain et al. reported that DZR decreased cardiac risk 
during DOX treatment 2.5-fold192. DZR is highly active in both adults and children, and 
prevents DOX-induced oxidative damage to cardiomyocytes without interruption of DOX 
anticancer activity193,194. Despite this, DZR use is limited due to severe exacerbation of 
DOX mediated myelosuppression195. 
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9. Conclusion 
Studies to improve the clinical potency, efficacy, and safety of DOX and its analogs 
are ongoing. DOX is the primary anticancer anthracycline in clinical use. It is hypothesized 
that the mechanisms of DOX action as an anticancer agent include the fast diffusion into 
the nucleus, where it intercalates between nucleotide base pairs of the DNA based on the 
planar ring structure of the aglycone. Following intercalation, covalent adducts to the DNA 
strand and DNA intrastrand cross-linkage are possible, as well as inhibition of 
topoisomerase II activity that leads to DSBs and interruption of DNA replication. 
Although DOX may be a useful chemotherapeutic due to its versatility in treating many 
tumor types, it causes adverse effects in cancer patients. The main adverse effect of DOX 
treatment is acute and chronic cardiotoxicity. This remains major problems to be resolved 
in DOX therapy. The mechanisms by which DOX induces cardiotoxicity include 
accumulation of reactive iron species (Fe2+ and Fe3+), formation of a toxic secondary 
alcohol metabolite by carbonyl reductases, overproduction of hazardous RONS, 
interference with calcium ion homeostasis, and mitochondrial dysfunction. Due to these 
therapeutic problems with DOX, the design of second and third generation DOX analogs 
to prevent cardiotoxicity and drug resistance, without losing the anticancer activity, has 
progressed. The development of DOX disaccharides, C-13 deoxy anthracyclines, 
liposomal formulations, and cardioprotective agents are new approaches to improve the 
therapeutic profile of anticancer anthracyclines. 
The goal of this study was to evaluate the ability of DOX derivatives to exert in vitro 
cytotoxic effects against various human STS and normal cells, and reduce tumor growth in 
an in vivo human STS xenograft model in nude mice. In addition, the ability of DOX 
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analogs to overcome drug efflux mediated drug resistance, inhibit topoisomerase II, and 
pharmacokinetics was characterized. The results indicate that the newest generation of 
analogs are promising anticancer agents that should not stimulate cardiotoxicity and should 
overcome drug resistance issues commonly encountered with DOX.
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CHAPTER TWO: IN VITRO AND IN VIVO ACTIVITY OF NOVEL DOXORUBICIN 
ANALOGS AGAINST SOFT TISSUE SARCOMA 
 
Abstract 
Two novel synthetic analogs (GPX-150, GPX-160) of the anticancer agent doxorubicin 
(DOX) were assessed for topoisomerase inhibitory activity and cytotoxicity against a panel 
of human soft tissue sarcoma, breast carcinoma, and normal cell lines. In vitro cytotoxicity 
experiments showed that GPX-160 generally exhibited sub-micromolar activity, with IC50 
values against cancer cells that were similar to DOX. In contrast, GPX-150 was uniformly 
less potent that either DOX or GPX-160. GPX-160 also retained equivalent sub-
micromolar potency against both DOX-sensitive (MES-SA) and DOX-resistant (MES-
SA/MX2) cell lines, suggesting reduced susceptibility to efflux pump mediated drug 
resistance found in the MES-SA/MX2 cell line. Finally, in an in vivo human xenograft 
model of fibrosarcoma, mice treated with GPX-150 and GPX-160 showed significant 
decreases in both tumor volume and tumor weight relative to control animals. 
1. Introduction 
Soft tissue sarcomas (STS) are a rare heterogeneous type of cancer that originate from 
mesenchymal cells1. STS accounts for approximately 1% of all adult malignancies and 8% 
of pediatric cancers2. While they can arise in any part of the body, STS more frequently 
occur in the extremities (50% of patients) or in the trunk/retroperitoneal areas (40% of 
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patients)1. More than 50 different histological types of STS are recognized by World Health 
Organization (WHO)3. Disease severity and prognosis relies on several factors including 
patient age and gender, tumor size, tumor spread, histological phenotype, and anatomical 
location4,5. 
STS treatment usually involves surgical resection of the primary tumor, followed by 
radiation, and/or chemotherapy1. The primary chemotherapeutic used to treat STS is 
doxorubicin (Adriamycin®), a water-soluble anthracycline first discovered in cultures of 
Streptomyces peuceitus var. caesius in the 1960s after the discovery of daunorubicin 
(DNR), its parent compound6,7. Doxorubicin (DOX) is a versatile chemotherapeutic that is 
also used to treat a wide array of other cancers, including leukemias, lymphomas, and solid 
tumors of the breast, ovaries, lungs and thyroid8,9. The primary mechanisms of anticancer 
activity are mediated by intercalation into DNA and subsequent inhibition of 
topoisomerase activity that ultimately interrupts DNA replication10. 
Although DOX is one of the major prescribed anticancer drugs, its use is clinically 
constrained due to well-known cardiotoxic side effects11. DOX treatment can cause both 
acute and chronic dose-dependent cardiotoxicity, which eventually leads to congestive 
heart failure. Acute cardiotoxicity can present itself within a week of a single dose of DOX 
treatment12,13, while chronic cardiotoxicity may occur 4-15 years after the completion of 
treatment14. The recommended cumulative dose of DOX is generally limited to less than 
500 mg/m2 to reduce the increasing risk of heart failure that occurs beyond 550 mg/m2 13,15-
18. Multiple mechanisms appear to be involved in DOX-induced cardiotoxicity, including 
its reduction to toxic doxorubicinol (DOXol) by cytosolic NADPH-dependent aldo-keto 
reductases (AKR1C3, AKR1A1, CBR1, CBR3)19-21, interruption of calcium and iron 
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homeostasis, and generation of reactive oxygen and nitrogen species (RONS)22,23. 
In order to improve the therapeutic profile of DOX, we analyzed synthetically modified 
DOX derivatives, GPX-150 and GPX-160 (Figure 1). These novel analogs were designed 
to reduce DOX-mediated cardiotoxicity by removing functional groups that promote 
formation of the toxic DOXol metabolite and reactive oxygen and nitrogen species 
(RONS), while retaining cytotoxicity against tumor cells. In the GPX-150 analog, the C-
13 carbonyl group was removed to prevent reduction to cardiotoxic DOXol. In addition, a 
carbonyl oxygen in the quinone ring was replaced with a nitrogen to create an 
iminoquinone with reduced capacity to stimulate formation of RONS24. The GPX-160 
analog was further derived from GPX-150 by replacing the primary amine at the 3’ position 
in the sugar moiety with a pyrrolino- group. This alteration in other analogs has been shown 
to enhance the binding to the DNA-drug ternary complex25,26 and to reduce the 
susceptibility to P-glycoprotein (P-gp) mediated drug efflux that is a common mechanism 
of drug resistance in tumor cells27. 
In this report, we evaluate the in vitro inhibitory activity of the DOX analogs against 
topoisomerase II α (Top2α), since this is a primary target of anthracycline action. The in 
vitro cytoxicity of the compounds against a panel of STS, carcinoma, and normal cells were 
also determined to investigate how alterations to chemical structure influence their 
Figure 2.1. The structures of DOX, GPX-150, and GPX-160. 
3’ 3’ 3’ 
13 13 13 
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anticancer profile. Finally, we report the comparative activity of DOX, GPX-150, and 
GPX-160 analogs in an in vivo murine xenograft model of human fibrosarcoma. The result 
demonstrates the efficacy of these analogs at reducing tumor growth and suggest their 
usefulness as novel anticancer agents. 
2. Results/Discussion 
2.1 Inhibition of Topoisomerase IIα 
DOX is a DNA intercalating agent that 
stabilizes the topoisomerase IIα (Top2α)-
DNA ternary cleavage complex to stall Top2α 
enzyme activity and interrupt DNA 
replication28. The ability of the DOX analogs 
to inhibit Top2α activity was investigated to 
gauge the effect of analog structural changes 
on this primary mechanism of drug action. 
Enzyme activity was studied using gel 
electrophoresis to examine Top2α 
decatenation of tangled kinetoplast DNA 
(kDNA) into its monomeric circular and linear 
forms. As seen in Figure 2A, incubation with 
increasing concentrations of GPX-160 
inhibited the appearance of decatenated 
circular kDNA. Based on densitometry of the 
electrophoretically separated reaction 
A 
            linear  circular 
kDNA   kDNA   kDNA                    GPX-160 (µM)              . 
  std       std        std         20         4        0.8      0.16       0 
  
B 
Figure 2.2 Topoisomerase inhibitory 
activity. [A] Representative agarose gel of 
Top2α-kDNA decatenation reaction 
products. High molecular weight catenated 
kDNA, low molecular weight linear kDNA 
and decatenated circular kDNA standards 
are seen in the first three lanes. The 
remaining lanes show Top2α reactions 
containing 0–20 μM of GPX-160. [B] Graph 
of Top2α activity based on densitometry of 
low molecular weight decatenated and 
linear kDNA bands. The graph shows the 
relative percent enzyme activity in DOX or 
GPX-containing reactions compared to 
uninhibited reactions. The IC50 results 
(inset) are the average of 4 experiments ± 
standard error of the mean (± SEM). 
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products, the concentration of DOX and GPX compounds required to inhibit 50% (IC50) 
of Top2α activity was estimated (Figure 2B). The IC50 of GPX-150 (1.15 µM) was 
approximately 3-4 fold higher than the IC50 for GPX-160 (0.32 µM) and DOX (0.23 µM). 
This finding may help explain the generally less potent in vitro cytotoxicity profile 
exhibited by GPX-150 as ascribed below. The findings also suggest that the alterations to 
DOX structure that reduce the GPX-150 inhibition of Top2α (loss of C-13 carbonyl, 
iminiquinone ring) are largely overcome by changing the 3’ amine group on the sugar 
moiety to the bulkier pyrrolino-group found in GPX-160, which appears to promote the 
formation of the ternary complex of drug-DNA-Top2α important for topoisomerase 
inhibition25. Our study shows the effect of 3’ substituents on the ability to stimulate Top2-
mediated DNA cleavage and is consistent with earlier studies29. 
2.2 Cytotoxicity studies 
The antiproliferative activities of DOX, GPX-150, and GPX-160 against a panel of 
seven STS, two breast carcinoma cell lines, and two normal cell lines were measured using 
a resazurin reduction assay30. Representative graphs of cytotoxicity profiles against DOX-
sensitive and DOX-resistant human uterine sarcoma lines are shown in Figure 3. DOX 
showed an IC50 of 0.56 µM for the drug sensitive MES-SA cell line, while the IC50 
increased about 25-fold to 13.3 µM for the drug-resistant MES-SA/MX2 line. This result 
is consistent with literature reports that attribute DOX resistance to the upregulation of P-
glycoprotein (P-gp) efflux protein expression27. In contrast, GPX-160 showed similar IC50 
values (0.76 µM and 0.73µM) against both the DOX sensitive and resistant MES-SA lines 
(Table 1). 
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Our results suggest that replacement of the 3’ amino group of the sugar with a 3’ 
pyrrolino- group reduces the drug susceptibility to P-gp activity. Supporting this 
observation, Frezard et al. (2001) reported that modification of anthracyclines with the 
electrophilic pyrrolino group decreased P-gp-mediated efflux kinetics and improved 
intracellular retention time31. Other investigators have also proposed that the C-3’ position 
in the sugar moiety is important not only as a substrate for P-gp mediated efflux, but also 
for impacting the sequence specificity and binding affinity of the drug in the minor groove 
of DNA25-27. 
The results of anticancer drug sensitivity studies are summarized in Table 1. GPX-150 
was the least potent analog, with IC50 values in the low micromolar range against sarcoma 
and carcinoma cells. These concentrations were generally an order of magnitude (or 
greater) than those found for DOX, which fairly consistently yielded sub-micromolar IC50 
values. Our in vitro antiproliferative efficacy of DOX showed similar results to previously 
reported studies against several STS32 and carcinoma cell lines33. With the exception of the 
Figure 2.3. In vitro drug sensitivity profiles for human uterine sarcoma cell 
lines, MES-SA (DOX sensitive, left) and MES-SA/MX2 (DOX resistant, right). 
The graphs represent the average of 3-5 independent experiments ±SEM. 
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HT1080 fibrosacroma cell line, GPX-160 showed sub-micromolar IC50 values against 
cancer cells. Overall, the GPX-160 cytotoxicity profile was more similar to DOX than to 
GPX-150. 
The cytotoxicity of DOX, GPX-150, and GPX-160 against two normal human cell 
lines, human adult dermal fibroblasts (HADF) and human umbilical vein endothelial cells 
(HUVEC-2) were also examined and are summarized in Table 2. Our IC50 values of DOX 
against fibroblast and endothelial cells correlate to previously reported studies34. Non-
proliferative HADF cells were insensitive to the compounds, with IC50 values of 
approximately 300 µM for all three drugs. Non-proliferative HUVEC-2 cells were also 
Table 2.1. Summary of drug activity against human sarcoma and carcinoma 
cell lines.  
 
Cell Line Tumor Type 
IC50 (μM)* 
 
DOX GPX-150 GPX-160  
HT1080 Fibrosarcoma 0.48 ± 0.21 47.6 ± 15.5 3.87 ± 0.50  
HT1080-luc2 Fibrosarcoma 0.73 ± 0.26 3.32 ± 0.59 3.51 ± 1.79  
RDCCL136 Rhabdomyosarcoma 0.43 ± 0.05 11.9 ± 3.99 0.44 ± 0.13  
SW-982 Synovial sarcoma 4.28 ± 1.46 0.80 ± 0.68 0.45 ± 0.14  
SW-872 Liposarcoma 0.35 ± 0.89 7.38 ± 0.45 0.57 ± 0.23  
MES-SA (DOXS) Uterine sarcoma 0.56 ± 0.08 10.6 ± 1.00 0.76 ± 0.16  
MES-SA/MX2 (DOXR) Uterine sarcoma 13.3 ± 1.68 17.8 ± 0.52 0.73 ± 0.04  
MCF-7 Breast carcinoma 0.34 ± 0.04 43.9 ± 9.13 0.44 ± 0.21  
MDA-MB-231 Breast carcinoma 0.20 ± 0.01 7.14 ± 1.92 0.17 ± 0.01  
*Expressed values are the mean (±SEM) of 3-5 independent experimental determinations. 
Table 2.2 Summary of drug activity against normal human cell lines.  
  Cell Type Cell Status 
IC50 (μM)* 
DOX GPX-150 GPX-160 
HADF Dermal 
fibroblast 
Proliferative 57.5 ± 14.8 19.2 ± 1.1   5.6 ± 1.2 
Non-proliferative  342 ± 123  322 ± 72.4  299 ± 68.0 
HUVEC-2 Umbilical 
endothelium 
Proliferative   5.4 ± 2.1 34.1 ± 10.4 14.0 ± 2.0 
Non-proliferative 41.9 ± 8.1  110 ± 22.6 33.9 ± 4.8 
*Expressed values are the mean (±SEM) of 3-5 independent experimental determinations. 
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resistant to compounds, although the IC50 values were at least 3-fold or lower than those 
seen for HADF cells. As expected, both normal cell lines showed increased sensitivity to 
all three drugs when they were in a proliferative state, with the IC50 values reduced to the 
5-50 µM range. These IC50 values were still generally 10- to 100-fold higher than those 
found for cancer cells. The results suggest that GPX-150 and GPX-160 will show 
selectivity for cancer cells that is similar to that seen with DOX. 
2.3 Inhibition of human sarcoma xenografts 
 The efficacy of GPX-150 and GPX-160 treatment on tumor growth was studied using 
luciferase-expressing human fibrosarcoma xenografts established in female (Foxn1nu) 
nude mice. Tumor growth was monitored using bioluminescent imaging (BLI) and caliper 
measurements in PBS, DOX, GPX-150, and GPX-160 treated mice (Figure 4). On day 20 
post-tumor engraftment, mice were imaged for the final time, and the tumor volume and 
weights were measured following euthanasia. PBS-treated (control) mice showed the 
largest tumors, averaging approximately 4100 mm3 or 3.1 g in weight (Figure 4, panel B 
and C). Reflective of their similar in vitro activities against the HT1080-luc2 cells (Table 
1), GPX-150 and GPX-160 treatment (2.4 mg/kg) resulted in similar decreases in tumor 
volume and weight. On average, treatment with the GPX compounds significantly 
decreased tumor volume by 71-76% and tumor weight by 60-67% relative to the PBS 
treatment (ρ < 0.0001). In contrast, mice treated with DOX (2.4 mg/kg) showed the most 
dramatic inhibition of tumor growth, with a 99% reduction in volume and 96% decrease in 
weight. Although this was a highly effective response to DOX treatment, the mice in this 
group exhibited the strongest signs of drug toxicity, based on poor activity, hunched 
appearance, and a 10% decrease in body weight relative to control animals (data not 
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shown). This result is consistent with other reports that have attributed these observations 
to the well-known cardiotoxic side effects of DOX35-37. 
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Figure 2.4. Effects of DOX, GPX-150, and GPX-160 treatment (2.4 
mg/kg) on human HT1080-luc2 fibrosarcoma xenograft tumor growth in 
female athymic nude mice (Foxn1nu). [A] Representative BLI of 
xenografts at the start (day 5) and end of treatment (day 20). [B] Average 
tumor volumes (± SEM) at sacrifice (day 20). [C] Average tumor weights 
(± SEM) at sacrifice (day 20). Graphs show the average of data collected 
from groups of 4 (PBS) or 5 (DOX, GPX-150, GPX-160) mice, each 
bearing 2 tumors. * ρ < 0.0001 when compared to PBS control treated 
mice.  
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3. Conclusion 
The biological activities of DOX and two novel DOX analogs, GPX-150 and GPX-
160, were characterized and compared. The analogs were designed to decrease potential 
cardiotoxic side effects of DOX by eliminating the C-13 carbonyl group and altering the 
quinone ring structure to an iminoquinone that produces less RONS formation. In addition, 
in the GPX-160 analog the 3’ amino group on the sugar in the GPX-160 analog was 
replaced with a pyrroline to improve intracellular retention. Both GPX-150 and GPX-160 
were potent inhibitors of human Top2α, although the IC50 value for GPX-150 (1.15 µM) 
was 3- to 5-fold higher than seen with either DOX or GPX-160. In in vitro antiproliferation 
assays against a panel of sarcoma and carcinoma cells, the IC50 values obtained for GPX-
160 were generally in the sub-micromolar range and resembled those found for DOX. 
GPX-160 was also consistently superior to GPX-150 in antiproliferative activity, probably 
due to decreased activity as a substrate for P-gp mediated drug efflux. Support for this 
assertion can be seen in the results from the MES-SA (DOXS) and MES-SA/MX2 (DOXR) 
cell studies. MES-SA/MX2 cells overexpress P-gp and showed a 20-fold increased 
resistance to DOX, but remained susceptible to GPX-160. This suggests that the 
incorporation of the bulkier pyrroline in place of the amino group of the sugar was 
successful in reducing efflux of the drug through P-gp. Finally, a pilot study using a human 
fibrosarcoma xenograft model in nude mice indicates that GPX-150 and GPX-160 are 
promising anticancer drugs with the ability to significantly reduce both tumor volume and 
weight. This finding is supported by the results of an initial clinical trial for GPX-150 
treatment of advanced sarcoma patients that was recently reported by Holstein et al.24. In 
this study, sarcoma patients treated with GPX-150 showed clinically significant 
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improvements in disease progression and no demonstrable drug-induced cardiotoxicity, 
although the required dose of GPX-150 was four-fold higher than what would be used for 
DOX. Future studies will include a more extensive examination of drug efficacy and 
delivery schedules in the HT1080-luc2 fibrosarcoma xenograft model. Considering the 
overall better antiproliferative profiles seen for GPX-160 in drug-resistant cells, future 
work will also include studies of efficacy using in vivo models of drug resistant tumors in 
mice. 
4. Materials and Methods 
4.1 Materials and Reagents 
GPX-150 and GPX-160 were supplied by Gem Pharmaceuticals, LLC (Birmingham, 
AL). DOX-HCl was purchased from Advanced ChemBlocks, Inc. (Burlingame, CA). All 
compounds were dissolved in 100% anhydrous dimethyl sulfoxide (DMSO) obtained from 
Sigma-Aldrich (St. Louis, MO) to 30 mM and stored frozen at -80 °C. Unless otherwise 
noted, all media and media constituents were purchased from Thermo Fisher Scientific 
(Pittsburgh, PA). 
4.2 Topoisomerase IIα Assay 
Top2 activities against antitumor agents were evaluated by observing the decatenation 
of kinetoplast DNA (kDNA), which consists of highly catenated networks of minicircular 
(2.5 kb) and maxicircular DNA (8 kb), using a Topoisomerase II assay kit (TopoGEN Inc., 
Buena Vista, CO). The measurement of decatenation activity is ATP-dependent and results 
in individual minicircles of DNA. The assay was performed in a reaction mixture (20 μl) 
containing 232 ng of kDNA, 2 units of human Top2, varying concentrations of test 
compounds, and assay buffer consisting of 50 mM Tris-HCl (pH 8), 155 mM NaCl, 10 mM 
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MgCl2, 0.5 mM dithiothreitol (DTT), 30 μg/ml boving serum albumin (BSA), and 2 mM 
ATP. DOX and DOX analogs were pre-incubated with kDNA for 6 hours at 37 °C prior to 
initiating the reaction by addition of enzyme. After 60 min incubation at 37 °C, the reaction 
was terminated with stop buffer to achieve a final concentration of 1% Sarkosyl, 0.025% 
bromophenol blue, and 5% glycerol. The reaction products were separated by 
electrophoresis on a 1% agarose gel submerged in 1x TAE buffer at 12V/cm, followed by 
ethidium bromide staining (0.5 μg/ml in 1x TAE). Gels were visualized and imaged using 
ultraviolet illumination on a FluorChem E gel imager (ProteinSimple, San Jose, CA). 
4.3 Cell Lines and Cell Culture 
Six human soft tissue sarcoma (STS) cell lines (HT1080, RDCCL, SW-982, SW-872, 
MES-SA, MES-SA/MX2) were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). The bioluminescent HT1080-luc2 fibrosarcoma line was 
purchased from Perkin Elmer (Waltham, MA). Normal human umbilical vein endothelial 
cells (HUVEC-2) and human adult dermal fibroblast (HADF) were purchased from 
Thermo Fisher Scientific. MCF-7 and MDA-MB-231 breast carcinoma were the kind gift 
of Dr. Cheryl Jorcyk (Boise State University). All cells were cultured at 37 °C with 5% 
CO2 in a humidified atmosphere. RDCCL136, SW-982, SW-872, MES-SA, MES-
SA/MX2, MDA-MB-231 and MDF-7 cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) 
penicillin/streptomycin (pen/strep). The drug-resistance phenotype of MES-SA/MX2 was 
maintained by culturing in the presence of 1 μM DOX until the assay treatment of DOX 
and DOX analogs. Huvec-2 and HADF were grown in complete endothelial growth 
medium and fibroblast medium, respectively (Sciencell Research Laboratories, Carlsbad, 
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CA). HT1080 and HT1080-luc2 were grown in Minimum Essential Medium (MEM), 
containing 10% FBS and 1% pen/strep. 
4.4 Antiproliferative Assays 
In vitro antiproliferative studies were performed using a resazurin reduction assay as 
previously described33. Briefly, cells were washed three times with sterile PBS (Thermo 
Fisher Scientific, Waltham, MA) and suspended in trypsin-EDTA (Lonza, Walkersville, 
MD) for less than 5 min at 37°C. Cells were centrifuged at 200 x g for 5 min and 
resuspended in the appropriate media to yield 250,000 – 400,000 cells/mL. Cells were 
seeded into sterile 96-well plates (5,000 – 8,000 cells/well) and then incubated overnight 
at 37°C in a 5% CO2 humidified atmosphere. The media was then replaced with 200 μl of 
fresh media with the appropriate concentration of drug. For cytotoxicity test against MES-
SA/MX2, 1 µM of DOX pressure was applied during cell culture prior to the drug 
treatment. Cells were incubated with drug for 48 h followed by addition of 20 µL of 0.1% 
(w/v) resazurin to each well. Fluorescence scans (excitation/emission: 530/590 nm) were 
obtained after 4-24 hours using a BioTek Synergy HT Multi-detection microplate reader 
(Winooski, VT). Fluorescence data was graphed as the % viability (Equation 1) versus 
drug concentration using GraphPad Prism software (La Jolla, CA). 
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
drug treated fluorescence−blank fluorescence
Drug−free fluorescence
 x 100                            𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 (1) 
The IC50 values of DOX and DOX analogs were determined using a non-linear fit of the 
% viability vs. log [drug]. 
4.5 In vivo Fibrosarcoma Xenograft Model 
The in vivo protocol was modified from Wang et al. (2010). All animal manipulations 
and protocols were conducted and approved by the Boise State University Institutional 
56 
 
 
Animal Care and Usage Committee #007-AC17-012 (IACUC). Four to five-week-old 
female immunodeficient mice (Hsd:Athymic Nude-Foxn1nu) were purchased from Envigo 
(Hayward, CA) and housed in the Boise State University vivarium. Animals were 
acclimated to the facility for two weeks prior to the beginning of the experiment. To create 
the fibrosarcoma xenografts, HT1080-luc2 cells were cultured and harvested as described 
as above, resuspended in sterile MEM (1 x 107 cells/mL) and placed on ice until injection. 
Mice were injected subcutaneously over both left and right shoulders with 0.1 mL tumor 
cells (1 x 106 cells per site). Mice were observed daily for tumor growth and overall health, 
and body weights collect three times per week. On day 5 following HT1080-luc2 cell 
injection, engrafted tumors were visualized by BLI. For BLI, mice were injected 
intraperitoneally (IP) with 0.2 mL sterile D-luciferin solution (15mg/mL in PBS), and the 
luciferin allowed to absorb for 10-15 min. The mice were then imaged using a Xenogen 
Spectrum IVIS instrument (PerkinElmer, Waltham, MA). Mice were randomly assigned to 
treatment groups (4-5 mice/group) consisting of drug (DOX, GPX-150, GPX160) or 
vehicle control (PBS). The mice received 100 μl of freshly prepared test compound (2.4 
mg/kg) three times per week by intraperitoneal (IP) injection for a total of six treatments 
(days 5, 7, 10, 12, 14, 17). Tumor size was measured three times a week with a Vernier 
caliper and the tumor volume calculated using the formula for an ellipsoid (Equation 2)38. 
𝑇𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 =
4
3
𝜋 ∙ (
𝐿
2
) · (
𝑊
2
) ∙ (
𝐻
2
)                                                      𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 (2) 
To image the luciferase labeled tumors, d-Luciferin potassium salt (PerkinElmer, 
Waltham, MA) was dissolved in sterile PBS at 10 mg/ml, and injected intraperitoneally 10 
min prior to image acquisition. BLI images were collected twice per week until day 21 
(sacrifice). Mice were sacrificed 21-days after tumor cell engraftment due to the excessive 
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enlargement of the tumor (> 1.5 cm3). Lungs and primary tumors were excised to determine 
metastasis and to measure the volumes and weights, respectively. The excised tumors and 
organs were preserved in the 10% formalin tissue fixatives (Sigma-Aldrich, St. Louis, MO) 
for further analysis. Prior to tumor injections, euthanasia, and BLI measurements, all the 
animals were anesthetized under isoflurane inhalation. 
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 CHAPTER THREE: ANALYSIS OF NOVEL IMINOQUINONE ANALOGS 
REVEALS DISTINCT IN VITRO PHARMACOKINETIC PROFILES 
Abstract 
Two iminoquinone analogs, GPX-150 and GPX-160, have been explored as 
anthracycline replacements to overcome cardiotoxic side effects and drug resistance 
profiles commonly encountered with doxorubicin (DOX) therapy. In vitro pharmacokinetic 
characteristics were determined to better understand how GPX-150 and GPX-160 compare 
to drug parameters displayed by DOX. Drug stability studies in serum containing media 
show that both analogs have 3-8 fold longer half-lives than DOX. The apparent 
permeability coefficients (Papp) across human epithelial colorectal adenocarcinoma (Caco-
2) cell monolayers demonstrate that both analogs show increased transepithelial transport 
rates in both apical (AP) to basolateral (BL) and BL to AP directions compared DOX. The 
results also show that the transepithelial efflux-to-uptake ratio of both GPX-150 and GPX-
160 are lower than DOX in the BL to AP direction. This suggest the analogs will be less 
sensitive to drug efflux and loss into the intestinal lumen. Human liver microsome 
cytochrome P450 (CYP450) metabolism of the analogs was examined with and without 
CYP450 selective inhibitors. The results showed that CYP2C8 and CYP3A4 were the most 
prevalent enzymes involved in modification of GPX-150 and GPX-160. Importantly, both 
analogs were insensitive to aldo-keto reductase (AKR) activity responsible for the 
conversion of DOX to cardiotoxic doxorubicinol. Mass spectrometry analysis of the liver 
microsomal drug products demonstrated metabolism of GPX-150 and GPX-160 occurred 
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through dealkylation, demethylation, and deglycosylation routes. Ultimately, the in vitro 
pharmacokinetics characterization of GPX-150 and GPX-160 will be useful in promoting 
their use as DOX replacements in cancer chemotherapeutic regimens. 
1. Introduction 
Doxorubicin (DOX, Adriamycin®) is a chemotherapeutic agent used for various forms 
of cancer such as breast and ovarian carcinoma, lung and pediatric cancers, lymphoma, 
leukemia, multiple myeloma, and soft tissue sarcomas1. The anticancer effects of DOX are 
known to be mediated through a number of mechanisms, but primarily by acting as a DNA 
intercalating agent that stabilizes the DOX-DNA-topoisomerase II ternary complex2. 
Despite the therapeutic successes of DOX, its clinical application is limited due to dose-
dependent acute and chronic cardiotoxicity that can lead to congestive heart failure 
(CHF)3,4. In addition, innate or acquired DOX resistance by cancer cells is a commonly 
encountered cause of treatment failure and necessitates the development of new 
chemotherapeutics5,6. 
Numerous mechanisms of DOX cardiotoxicity have been studied and proposed7. One 
of the major mechanisms responsible for DOX cardiotoxicity is the aldo-keto reductase 
(AKR) mediated reduction of the C-13 carbonyl group to the corresponding alcohol 
metabolite, doxorubicinol (DOXol)8,9. DOXol accumulates in the cardiomyocyte and is up 
to ten-fold more potent than DOX in stimulating cardiotoxicity10. DOXol inhibits the Na+-
K+ pump of the cardiomyocyte sarcolemma, interrupting ion signaling involved in cardiac 
contraction and leading to CHF11. 
To prevent the formation of DOXol and overcome the undesirable side effects of DOX, 
the iminoquinone analogs GPX-150 and GPX-160 were developed (Figure 1)12. GPX-150 
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contains two structural changes from DOX: the elimination of the C-13 carbonyl group to 
prevent formation of DOXol, and the replacement of a carbonyl in the quinone ring to 
create an iminoquinone with reduced capacity to generate reactive oxygen and nitrogen 
species (RONS)11–15. GPX-160 retains the basic structure of GPX-150, but replaces the 
primary amine on the sugar with a pyrrolino group that is proposed to reduce its 
susceptibility to P-glycoprotein (P-gp) mediated efflux [PMID: 21075206]. GPX-150 and 
GPX-160 display in vitro cytotoxicity and efficacy profiles that are comparable to DOX 
(see chapter 2). 
The purpose of this study is to better understand in vitro pharmacokinetics of GPX-150 
and GPX-160 relative to the parent DOX compound. The analogs were evaluated for drug 
stability, fluorescence profiles, in vitro intestinal permeability, and identification of the 
CYP450 isozymes involved in their metabolism. Using liquid chromatography tandem 
mass spectrometry, metabolic breakdown products of DOX and it analogs were identified 
and compared. Ultimately, these studies illuminate aspects of basic drug characteristics 
that demonstrate several superior features for the analogs over DOX, and serve as useful 
background information for future drug development and predicting the behavior of these 
compounds in clinical trials. ADD Mitchell’s Intro Sentence HERE. 
 
 
 
Figure 3.1. The structures of doxorubicin, GPX-150, and GPX-160. 
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2. Materials and methods 
2.1 Drug stability studies 
The stability of DOX, GPX-150, and GPX-160 in a biological environment was 
examined by diluting samples of drug stock solutions (10 mM in DMSO) to a final 
concentration of 250 µM in Dulbecco’s Minimal Essential Medium (DMEM) containing 
10% fetal bovine serum (FBS) (v/v) and 1% pen/strep (100 U/ml penicillin and 100 μg/ml 
streptomycin). Samples were vortexed briefly to mix, filtered through 0.22 µm PTFE 
syringe filters, and analyzed by high-performance liquid chromatography (HPLC). 
Analysis was performed on a 50 mm x 4.6 mm Hypersil GOLD phenyl column (5 μm pore 
size) using an Agilent 1100 series HPLC equipped with a diode array detector. Mobile 
phases A and B consisted of 52 mM Tris base (pH 7.2) and 99.9% HPLC-grade acetonitrile, 
respectively. Gradients were conducted with a flow rate of 1.0 ml/min for 15 min with the 
following linear program: t = 0 min (70%; A, 30%; B), t = 10 min (30%; A, 70%; B), 
t=12min (30%; A, 70%; B), t=12.1min (70%; A, 30%; B), and t = 15 min (70%; A, 30%; 
B). Samples (20 µL) were injected every 15 min until near complete decomposition was 
observed. The retention times for DOX, GPX-150, and GPX-160 were 4.3, 3.8, and 4.9 
minutes, respectively. Drug decomposition was observed as decreases in integrated peak 
areas. Drug half-lives were calculated from plots of integrated peak area vs. time, and fit 
using one-phase decay based on first-order kinetics. 
2.2 Drug transport studies 
To develop epithelial cell monolayers, 1.5 x 105 Caco-2 cells (ATCC, Manassas, VA) 
were seeded in 24-well plates containing Transwell® permeable polycarbonate inserts (6.5 
mm diameter; Corning, Tewksbury, MA) and cultured in -MEM (Thermo Fisher 
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Scientific, Waltham, MA) supplemented with 10% FBS and 1% pen/strep. The media was 
replenished every 2 day. The plates were incubated at 37 °C in a 5% CO2 humidified 
atmosphere for 21 days until the cell monolayers were fully developed. In the polarized 
cell monolayers, the apical and basolateral sides face the upper and lower transwell 
chamber, respectively. The integrity of the polarized monolayers was evaluated by 
transepithelial electrical resistance (TEER) measurements using an EVOM2 epithelial 
voltohmmeter (World Precision Instruments Inc., Sarasota, FL). Transport studies were 
initiated when the TEER values of each well surpassed 300 Ω•cm2. TEER values of 555 ± 
32 Ω•cm
2
 at 37 °C, and low Lucifer yellow (LY) permeability rates (< 0.5x10-5 cm/s) indicate good 
integrity of the Caco-2 monolayer. 
For transport experiments, both upper and lower Transwell® chambers were washed 
three times with pre-warmed 1x Hank’s balanced salt solution (HBSS, HyClone 
Labratories. Inc., Logan, UT). After washing, the plates were incubated in fresh HBSS for 
30 min at 37 °C. For the apical to basolateral (AP-BL) uptake experiment, 450 μl of test 
solutions (25 µM drug) was added to the AP side, and 1600 μl of pre-warmed HBSS was 
added to the BL well chamber. LY (25 µM) served as a control for non-specific paracellular 
transport. At intervals of 30, 60, 90, 120, 150 min later by removing 200 μl from the BL 
chamber. This volume was replaced with an equivalent volume of fresh HBSS. The plates 
were incubated in an orbital shaker at 37 °C at 50 rpm between the time intervals. 
To evaluate the BL-AP drug efflux of the test compounds, 1600 μl of the test solutions 
(containing 50 µM drug in HBSS) was added to the BL chamber, while 450 μl of HBSS 
without test compound was added to AP side. A 150-μl aliquot was collected from the AP 
side at time intervals of 30, 60, 90, 120, and 150 min, and was replaced with an equivalent 
volume of HBSS. Sample concentrations were assessed using a BioTek fluorescence 
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microplate reader with the following settings: DOX (ex. 490/em. 590 nm); GPX-150 (ex. 
560nm/ em. 630nm); and GPX-160 (ex. 560 nm/ em. 630 nm). The amount of transported 
durg was determined from standard curves of drug concentration versus fluorescence. The 
apparent permeability coefficients (Papp, cm/s) for the test compounds were determined 
according to the following equation18: 
 Papp = (dCr/dt) x Vr / (A x C0)                                                     Equation (1) 
where dCr/dt is the change of concentration of test compounds in the receiver chamber 
(μg/s), Vr is the volume of receiver chamber, A is the area of the inserts (0.33 cm
2), and Co 
is the initial concentration of drugs (50 μM). The efflux ratio was determined as: 
 Efflux ratio (ER) = Papp (BL-AP) /Papp (AP-BL)                                 Equation (2) 
2.3 Microsomal metabolism of DOX and DOX analogs 
The initial rates of DOX and DOX analog metabolism by human liver microsomes 
(HLMs) were determined based on the method of Quintieri et al.19 that follows the change 
in fluorescence of the reaction as NADPH is oxidized to NADP+. The 2-ml reaction 
mixture consisted of 0.1 M potassium phosphate (pH 7.4), 0.15 mM NADPH, and 50 μM 
DOX or DOX analog. The reaction was preincubated for 3-minute at 37°C, and initiated 
with the addition of 0.1 mg/ml HLMs (50 donor pool, Sekisui XenoTech LLC, Kansas 
City, KS) containing approximately 50 nmol CYP450 protein. Controls consisted of 
reactions conducted without microsomes, without NADPH, or without test drug. All 
reactions were tested in triplicate using a Cary Eclipse spectrofluorometer (Varian, Palo 
Alto, CA) and scanned (ex. 340 nm/em. 460 nm) for 1 hour at 37 °C. 
To begin to identify the microsomal enzymes responsible for GPX-150 and GPX-160 
metabolism, fluorometric HLM assays (above) were conducted in the presence and absence 
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of aldo-keto reductase (AKR), alcohol dehydrogenase (ADH), or CYP450 isozyme 
specific enzyme inhibitors selected based on literature reports11,15-17. All inhibitors were 
obtained from Sigma-Aldrich (St. Louis, MO). ADH- and AKR-specific inhibition was 
measured using 50 µM 4-methylpyrazole (ADH) or 50 µM quercitrin (AKR), or. For CYP 
specific inhibition, the following selective inhibitors were used: 10 µM xanthotoxin 
(CYP2A6), 60 µM quercetin (CYP2C8), 30 μM sulfaphenazole (CYP2C9), 10 μM 
quinidine (CYP2D6), 5 μM ketoconazole (CYP3A4). 
2.4 Identification of DOX and DOX analog metabolic products by mass spectrometry 
HLM metabolites of DOX, GPX-150, and GPX-160 were identified using HPLC and 
mass spectrometry (HPLC-MS). HLMs assays were performed as described above, but 
modified to contain 50 µM test drug and scaled to a final volume of 400 µl. Controls 
consisted of reactions with denatured microsomes (45 °C / 30 min), reactions without 
NADPH, or reactions without test drug. Reactions were terminated after 60 minutes at 37 
°C with the addition of 400 μl ice-cold acetonitrile. Precipitates were removed by 
centrifugation at 10,000 x g for 30 min. Sample aliquots (20 µl) were injected onto a 
Hypersil GOLD phenyl analytical column (50 mm x 4.6 mm) using an Agilent 1100 HPLC 
coupled to a HCTultra ETDII electrospray ionization mass spectrometer (Bruker Daltonik 
GmbH, Bremen, Germany). Chromatographic separations were achieved using a 1 mL/min 
flow rate of 79 mM ammonium formate (Solvent A, pH 4.2) and 100% acetonitrile (solvent 
B) as mobile phases. A gradient elution program: t = 0 min (70% A, 30% B), t = 10 min 
(30% A, 70% B), and t = 12.1 min (70% A, 30% B) was used. Doxorubicin elution was 
detected at 495 nm. GPX-150 and GPX-160 elution were detected at 560 nm. The retention 
times of DOX, GPX-150, and GPX-160 were 4.1, 4.1, and 5.2 minutes, respectively. 
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The mass spectrometer was operated in positive ion mode using a 6 kV of source 
voltage. Data were collected under full scan mode from 100 – 800 m/z and analyzed using 
an Esquire 6000 software program. Nine m/z values (544.2, 529.2, 581.2, 382, 364, 346, 
321, 200, and 147 m/z) were used to conduct an enhanced quadratic calibration within the 
expected mass range of fragments of the compounds. 
3. Results 
3.1 Drug stability of DOX, GPX-150, and GPX-160 
Drug decomposition rates in media containing serum 
were determined to compare the stability of the analogs to 
DOX. As seen in Figure 2, the average half-life of DOX 
was at 6.8 hours. Compared to DOX, GPX-150 was 
approximately 8-fold more stable (t1/2 = 55.9 h) and GPX-
160 was 3-fold more stable (t1/2 = 20.7 h). The stability of 
the drugs in nanopure water was substantially longer (data 
not shown), suggesting that serum constituents play a role 
in the drug breakdown. 
3.2 Transport studies of DOX analogs across intestinal 
epithelia  
The in vitro transport rates of DOX, GPX-150, and GPX-160 were evaluated using 
mature, polarized Caco-2 cell monolayers to simulate the human intestinal environment. 
In the assay, monolayer integrity was indicated by examining the transport of hydrophilic 
Lucifer yellow (LY) dye, which is poorly transported across the intact epithelial cell 
membrane bilayer20. The apparent permeability coefficients (Papp) for DOX, GPX-150, and 
 
Figure 3.2. Drug 
degradation of DOX, GPX-
150, and GPX-160. Drug 
half-lives were determined 
based on one phase decay 
analysis of integrated peak 
areas from HPLC. 
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GPX-160 were evaluated as a preliminary investigation into transport capability across the 
intestinal epithelia. As seen in Figure 3 and summarized in Table 1, measurements of basal 
to apical (BL-AP) permeability coefficients indicate that GPX-150 and GPX-160 have 
significantly greater efflux (p≤ 0.05) across the monolayer relative to DOX. Similarly, 
apical to basal (AP-BL) permeability coefficients that were significantly higher in GPX-
150 and GPX-160 (p ≤ 0.05 and p ≤ 0.01) compared to DOX. The results show that GPX-
150 and GPX-160 are much more permeable across the monolayer in either direction than 
DOX. When the ratio of efflux-to-uptake is considered, DOX exhibits a strong preference 
for BL-AP efflux with a Papp ratio of 2.5 (Figure 3). In contrast, GPX-150 and GPX-160 
exhibited ratios near 1, which indicates no strong preference for direction of transport. 
                        A                                    B                                           C
Figure 3.3. Apparent permeability rates (Papp, cm/s) of DOX, GPX-150, 
and GPX-160 transport in basal to apical (A) and apical to basal (B) 
directions. The figures show the average of three independent experiments (± 
SEM). * and ** represent p≤ 0.05 and p≤ 0.01, respectively. The efflux ratio 
(C) explains the ratio of average permeability rates of efflux (BL-AP) to 
uptake (AP-BL) across the epithelial monolayer. 
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3.3 Microsomal metabolism of DOX and DOX analogs 
The preliminary data on the microsomal metabolism of DOX, GPX-150, and GPX-160 
was determined by examining the loss in fluorescence (ex. 340 nm / em. 460 nm) of a 
reaction that accompanies the corresponding oxidation of NADPH to NADP+. As seen in 
Figure 4 (upper left panel), the microsomal oxidation rate of NADPH when GPX-150 or 
GPX-160 were substrates was approximately half that seen for DOX.  
The application of selective inhibitors to the HLM assays provided initial information 
on the enzyme activities important for DOX, GPX-150, and GPX-160 metabolism. The 
results of the analysis show that DOX metabolism was inhibited by 40-85% when 
inhibitors of five CYP450 isoforms (2A6, 2C8, 2C9, 2D6, 3A4), alcohol dehydrogenase 
(ADH) or aldo-keto reductase (AKR) were incorporated into the reactions (Figure 4). Of 
these results, quercetin (CYP2C8-selective, 85% inhibition), ketoconazole (CYP3A4-
selective, 70% inhibition) and quercitrin (AKR-selective, 81% inhibition) showed the 
greatest effects, indicating that CYP2C8, CYP3A4, and AKR were most important 
enzymes in DOX microsomal metabolism.  
In contrast to DOX, GPX-150 and GPX-160 metabolism was relatively insensitive (≤ 
20% inhibition) to xanthotoxin (CYP2A6-selective), sulphenazole (CYP2C9-selective), 
quinidine (CYP2D6-selective), 4-methylpyrazole (ALDH-selective), or quercitrin (AKR-
Table 3.1. Summary of apparent permeability rates (Papp) of 
bidirectional drug transport. 
                                Ave. Papp (x10-6 cm/s)* 
 LY** DOX GPX-150 GPX-160 
BL to AP 4.0 ± 1.4 20.0 ± 5.0     42.0 ± 5.8 50.1 ± 10.5 
AP to BL 4.8 ± 2.4   8.3 ± 4.0  32.4 ± 12.8 43.3 ± 10.0 
Efflux ratio 0.83 2.46 1.30 1.16 
* Average of 3 experiments ±SEM.  ** Lucifer yellow control 
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selective). The most striking inhibition of GPX-150 and GPX-160 metabolism occurred 
only when reactions contained quercetin (CYP2C8-selective, ~ 60% inhibition) and 
ketoconazole (CYP3A4-selective inhibitor, ~ 50-70% inhibition.). As expected based on 
the loss of the C-13 carbonyl group and poor quercitrin inhibition (AKR-selective), aldo-
keto reductase activity was not an important factor in GPX-150 or GPX-160 metabolism. 
 
 
Figure 3.4 HLM metabolism of DOX, GPX-150, and GPX-160. NADPH oxidation 
rates were > 2-fold higher for DOX than for the DOX analogs (upper left panel). The 
remaining panels show percent metabolic activity (compared to uninhibited 
reactions) when selective cytochrome P450, ADH, or AKR inhibitors were 
incorporated into the reactions. The selective inhibitors were xanthotoxin (CYP2A6), 
quercetin (CYP2C8), sulfaphenazole (CYP2C9), ketoconazole (CYP3A4), quinidine 
(CYP2D6), 4-methylpyrazole (ADH), and quercitrin (AKR). *represents p ≤ 0.0001 in 
comparison to DOX. 
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3.4 Identification of DOX and DOX analog metabolic products 
The products of HLM metabolism of DOX, GPX-150, and GPX-160 were analyzed by 
reverse phase HPLC-tandem mass spectrometry (Figure 5). The primary DOX peak eluted 
at 4.1 minutes. NADPH in the reactions eluted at 1.9 minutes (data not shown) without 
overlapping other compounds (i.e 
CYP450 inhibitors and the anticancer 
compounds). DOX metabolites (DOXol, 
etc) were primarily detected at a retention 
time of 2.4-2.6 minutes and identified by 
mass spectrometry. Mass spectra and a 
schematic for the metabolic 
decomposition of DOX can be found in 
Appendix B.  
GPX-150 showed a retention time of 
4.1 minutes on the HPLC chromatogram, 
and the majority of its metabolites eluted 
at 2.8 minutes (Figure 5B). The mass 
spectra and a schematic for the metabolic 
decomposition of GPX-150 can be found 
in Appendix B.  
GPX-160 and its metabolites (M) 
showed retention times of 5.2 and 4.7 
minutes, respectively (Figure 5C). The 
Figure 3.5. HPLC elution profiles for 
HLM reactions containing (A) DOX, (B) 
GPX-150, and (C) GPX-160. The spectra 
were collected at the λmax for the 
respective compounds: DOX (495 nm), 
GPX-150 and GPX-160 (560 nm). The 
retention times for DOX, GPX-150, and 
GPX-160 were 4.1, 4.1, and 5.2 minutes, 
respectively. Metabolites (M) were 
eluted at 2.5, 2.8, and 4.7 minutes. 
 
DOX
M
GPX-150
M
GPX-160
M
T im e  ( m in )
m
A
U
0 5 1 0 1 5
0
5 0
1 0 0
1 5 0
(B)
(C)
(A)
T im e  ( m in )
m
A
U
0 5 1 0 1 5
0
1 0
2 0
3 0
4 0
T im e  ( m in )
m
A
U
0 5 1 0 1 5
0
1 0
2 0
3 0
4 0
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mass spectra for GPX-160 and its metabolites can be seen in Figure 6. The identity of the 
metabolic breakdown products of GPX-160 was assigned using the mass spectra 
fragmentation pattern (Figure 6), and predictions of how the compound would be expected 
to be metabolized based on literature reports of the mass spectra of CYP450 
decompositions of DOX19. 
A summary of the compounds identified in the mass spectra of HLM metabolized 
DOX, GPX-150 and GPX-160 is found in Table 2. DOX has an observed characteristic 
Figure 3.6. Mass spectra of GPX-160 [M+H]+ and its HLM metabolites. F1 
denotes a GPX-160 fragment with a characteristic loss of the sugar moiety. The 
major metabolites (M1-M5) of GPX-160 eluted at 4.6 - 4.7 minutes from the HPLC 
and correspond to the predicted 4-O-demethylation (M1), 5’-demethylation (M2), 
dealkylation (M3), hydroxyaglycone (M4) and 7-deoxyaglycone (M5) products. 
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[M+H]+ peak at 544.17 m/z and a minor peak at 397.1 (F1) that agrees with the predicted 
mass of a deglycosylated fragment (Appendix B). Cardiotoxic DOXol, the AKR metabolite 
of DOX, appears in the spectra as a peak at 546.75 m/z, close to its predicted 546.19 m/z 
peak. Fragments corresponding to demethylation, dealkylation, and deglyosidation 
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reactions of DOX, particularly those catalyzed by CYP2C8 and CP3A4 were observed 
(Table 2A). 
The [M+H]+ fragment of GPX-150 was found at 529.2 m/z and its expected CYP2C8 
and CP3A4 induced metabolites were observed as a series of 384 – 515 m/z peaks. A GPX-
Table 3.2. Identities of the m/z peaks in the mass spectra of HLM metabolized 
(A) DOX, (B) GPX-150, and (C) GPX-160. 
(A) 
Peaks 
Compounds 
/reaction 
Measured 
m/z 
Theoretical 
m/z 
Error 
(ppm) 
Retention time 
(min) 
1 Doxorubicinol 546.7500 546.1897 1025.8 2.5 
2 Doxorubicin 544.1644 544.1741 17.8 4.1 
3 Dealkylation 486.2882 486.1686 246.0 2.4 
4 Doxorubicinone 415.1250 415.0951 72.0 2.6 
5 7-deoxydoxorubicinol 401.1587 401.1158 107.0 2.5 
6 7-deoxydoxorubicinone 399.1886 399.1002 221.5 2.5 
7 F1 397.0806 397.0923 29.5 4.1 
8 Demethylation 387.0625 387.1002 97.4 2.5 
9 F2 379.1376 379.1182 51.2 2.4 
10 F3 321.0823 321.0763 18.7 4.1 
 
(B) 
Peaks 
Compounds 
/reaction 
Measured 
m/z 
Theoretical 
m/z 
Error 
(ppm) 
Retention time 
(min) 
1 GPX-150 529.1987 529.2108 22.9 4.1 
2 4-O-demethylation 515.2496 515.1951 105.8 2.8 
3 Dealkylation 485.2241 485.1846 81.4 2.8 
4 F1  400.1268 400.1318 12.5 4.1 
5 Hydroxyaglycone   400.125 400.3900 661.9 2.8 
6 7-deoxyaglycone 384.0625 384.1369 193.7 2.8 
7 F2 (loss of water) 382.1305 382.1576 70.9 4.1 
 
(C) 
Peaks 
Compounds 
/reaction 
Measured 
m/z 
Theoretical 
m/z 
Error 
(ppm) 
Retention time 
(min) 
1 GPX-160 581.2654 581.2499 26.7 5.2 
2 4-O-demethylation 567.2658 567.2343 55.5 4.7 
3 5'-demethylation 553.2239 553.2186 9.6 4.7 
4 Dealkylation 537.1425 537.2237 151.1 4.7 
5 Hydroxyaglycone 400.2021 400.3900 469.3 4.6 
6 F1 400.1167 400.1318 37.7 5.2 
7 7-deoxyaglycone 384.1250 384.1369 31.0 4.6 
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160 m/z value was found at 581.26, as well as its proposed demethylated (M1, M2), 
dealkylated (M3) and deglycosylated (M4, M5) products between 384 - 567 m/z. A 
schematic of the proposed metabolic routes of GPX-160 is presented in Figure 7. 
 
4. Discussion 
This pharmacokinetic study was conducted to describe the in vitro stability, transport 
and metabolism of novel iminoquinone analogs of DOX in order to forecast in vivo drug 
characteristics of the compounds when they are used as anticancer agents. 
Good drug stability can facilitate improved drug retention and distribution of potential 
candidates for cancer treatment21,22. To evaluate the drug degradation rates, we tested 
morphologically modified DOX derivatives that replaced the quinone structure with an 
iminoquinone to decrease the potential to produce reactive oxygen species associated with 
acute cardiotoxicity. The iminoquinone GPX-150 clearly shows an 8-fold increase in drug 
stability relative to DOX. 
The removal of the C-13 carbonyl from GPX-150 and GPX-160 could increase the 
hydrophobicity of the compounds, which could result in increased lipophilicity longer 
blood circulation time and higher accumulation in tumors23. GPX-160 showed a 3-fold 
Figure 3.7. Schematic of proposed GPX-160 metabolites by CYP2C8 and 
CYP3A4. 
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increase in stability relative to DOX, but was less stable than GPX-150. Increased stability 
in our assay is potentially due to the less reactive nature of the iminoquinone found in GPX-
150 and GPX-160. Compared to GPX-150, the reduced stability of GPX-160 may be due 
to the positively charged 2-pyrrolino moiety, which is a stronger electrophile than the 
primary amine of GPX-150. Potentially, this could lead to GPX-160 non-specifically 
reacting with proteins and other biological constituents in the media. 
This study also evaluated the bidirectional transcellular transport pathway of DOX, 
GPX-150, and GPX-160. The lack of a C-13 carbonyl makes both GPX-150 and GPX-160 
more hydrophobic than DOX. This potentially explains the increased transport rate of these 
compounds in both the AP to BL and BL to AP directions. Numerous studies have defined 
the permeability coefficient less than 1x10-6 cm/s exhibits poor (0-20%), between 1x10-6 
cm/s and 10x10-6 cm/s shows moderate (20-70%), and greater than 10x10-6 cm/s displays 
substantial absorption (100%)24. Since GPX-150 and GPX-160 show transport rates of 30-
50 x10-6 cm/s, these compounds would be classified as substantially absorbed. In contrast, 
DOX represents a moderately observed compound. Increased transport rates suggest that 
GPX-150 and GPX-160 could potentially be delivered orally to treat cancer. However, 
further investigation of oral bioavailability such as in vivo studies are necessary to fully 
estimate the potential for these compounds to be useful by oral administration. 
Furthermore, ratio of efflux to absorption of the anticancer drugs were determined from 
ratio between the Papp of BL to AP and AP to BL (Figure 3). DOX shows almost 2.5-fold 
higher in BL to AP than AP to BL pathway indicating a high ER (Table 2), which yields 
lower cellular uptake of DOX in the intestinal environment as a safety mechanism to 
protect the body from xenotoxins25. In contrast, GPX-150 and GPX-160 show ER that are 
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evenly balanced between BL to AP and AP to BL (ER near 1). 
The metabolism of DOX, GPX-150, and GPX-160 was initially established using a 
NADPH-mediated reaction with HLMs. Further, the CYP450 isozymes responsible for the 
drug metabolism was explored using selective CYP inhibitors identified from reported 
studies of DOX metabolism60-62. The faster oxidation rate of NADPH to NADP+ in DOX 
metabolism is due to the presence of the C-13 carbonyl group that is the substrates for 
carbonyl reductase (CR), which is a member of the aldo-keto reducatase (AKR) family, is 
a major AKR enzyme that reduces DOX to DOXol in the cardiomyocyte26. DOXol is very 
potent in inducing chronic progressive cardiotoxicity and eventually causes CHF27. 
Without the presence of C-13 carbonyl in side chain, the oxidation of NADPH in reactions 
containing GPX-150 and GPX-160 diminishes as the main active site of CR disappears. 
The importance of CR interaction with quinone ring of DOX has also been explained by 
enzymatic and computational studies28. 
CYP3A4 participates in approximately 50% of CYP450 of the drugs oxidative 
metabolism examined up to date30. In adults, 29% of the liver CYP450 enzyme expression 
is CYP3A431, while  this value rises to 50% in the small intestine32. It is the most abundant 
of all of the human CYP isoforms, and is localized in the GI tract, kidney, and liver where 
it is particularly relevant to drug elimination33. The results of our studies show that 
CYP2C8 and CYP3A4 are the most significant CYP450 isozymes responsible for the 
biotransformation of DOX, GPX-150, and GPX-160. The CYP3A4 metabolism of these 
compounds is consistent with the reported literature39-41. Interestingly, CYP3A4-mediated 
metabolism is also required to transform the pro-drug MMDX (PNU-152243) into the 
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active DOX derivative, a compound which was explored in phase I and II clinical trials as 
an anticancer agent29. 
Our results also showed that CYP2C8 is involved in DOX, GPX-150, and GPX-160 
metabolism which is consistent with a literature34. Other studies have shown that CYP2C8 
is responsible for the metabolism of numerous drugs including tetracyclic compounds35,36. 
CYP2C8 is regulated by the expression of the pregnane X receptor (PXR), which 
stimulates expression of P-gp that increase drug resistance of human lung carcinoma37. 
Defining the pharmacologic and toxicologic profiles of xenobiotics is an important 
prelude to clinical trials. HPLC-MS-MS analysis was used to separate and identify the 
parent compounds and their biotransformation products. Based on the major roles of 
CYP2C8 and CYP3A4 in GPX-160 metabolism, a proposed schematic of metabolites is 
shown in Figure 9. The m/z value of the GPX-160 parent ion was 581.26. CYP2C840 and 
CYP3A441 deglycosidation products of GPX-150 and GPX-160 by hydrolytic or reductive 
cleavage of the sugar moiety generated the same aglycones with peaks at 400.39 and 
384.14 m/z, respectively. Furthermore, CYP3A4-specific dealkylation of GPX-160 would 
be predicted to yield a fragment with an m/z value of 537.143, which is supported by the 
mass spectra (Figure 6). The remaining demethylation or deglycosidation products seen in 
mass spectra could be formed by the action of either CYP2C8 or CYP3A4. 
Similar to GPX-160, the aglycone metabolites of GPX-150 were assumed to be 
produced by both CYP2C8 and CYP3A4 due to their roles in deglycosidation reactions. In 
GPX-150, this corresponds to metabolites peaks with m/z values at 400.39 and 384.14, 
respectively (Appendix B). These represent aglycones formed by hydrolytic or reductive 
mechanisms. Furthermore, the peaks at m/z of 515.52 and 485.18 suggest demethylation44 
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and dealkylation reactions by CYP3A443. The peak at 382.1 m/z is in agreement with the 
cleavage of the sugar residue from GPX-150 with subsequent loss of a water molecule. 
In the mass spectra of DOX (Appendix B), the main peak occurs with a m/z of 544.16. 
Notable peaks with m/z values of 397.1 and 379.1 can be explained by the protonation of 
DOX at C-7, loss of the sugar residue, and subsequent collision induced loss of water38,39. 
The peak at 321 m/z is consistent with the loss of both the sugar moiety and the alkyl side 
chain at C-919. The peaks at m/z 415.2 and 399.2 represent glycosidic cleavages yielding 
hydrolytic (doxorubicinone) and reductive (7-deoxydoxorubicinone) aglycones. These are 
predominantly formed by CYP2C840 and CYP3A441. Further reduction of the C-13 
carbonyl by carbonyl reductase result in 7-deoxydoxorubicinone that corresponds to the 
peak at 401.12 m/z. Doxorubicinone can also be reduced by carbonyl reductase to yield 
doxorubicinolone42. The peaks at 486.7 and 387.1 m/z correspond to CYP3A4-mediated 
dealkylation of the side chain and demethylation of 7-deoxydoxorubicinone, 
respectively43. 
As with DOX, metabolites of GPX-150 and GPX-160 may show unique toxicities. 
However, these are not yet identified. Potentially co-administration of potent inhibitors of 
CYP2C8, such as quercetin or glitazones45 and/or inhibitors of CYP3A4, such as azole 
antifungals (e.g., ketoconazole and itraconazole)35 and macrolide antibiotics (e.g., 
erythromycin and troleandomycin)46, could preserve the chemotherapeutic efficacy of 
GPX-150 and GPX-160. This may be useful when using these analogs to treat certain 
human carcinomas including hepatocellular carcinomas that show increased CYP3A4 
expression44. 
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5. Conclusion 
In conclusion, our studies show that GPX-150 and GPX-160 have increased biological 
stability and transport rates relative to DOX across Caco-2 monolayers. This suggests they 
may have potential for oral delivery. The results of our in vitro studies using CYP450 
selective inhibitors demonstrated that the two analogs were predominantly metabolized by 
CYP2C8 and CYP3A4. Importantly, the absence of a C-13 carbonyl group abrogated CR-
mediated formation of toxic alcohol metabolites and significantly decreased microsomal 
drug metabolism. This suggests that these analogs could persist longer in vivo than DOX. 
Mass spectrometry analysis of the microsomal drug metabolites was consistent with 
predictions of CYP2C8- and CYP3A4-mediated metabolism based on known degradation 
pathways of DOX. Future animal studies will expand our understanding of the absorption, 
distribution, metabolism, and excretion (ADME) of these novel DOX analogs. 
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CHAPTER FOUR: CONCLUSION 
DOX is among the most prominent and versatile antitumor agents used to treat a variety 
of cancer patients. The antineoplastic mechanism of DOX primarily involves intercalating 
DNA between base pairs, creating DNA adducts, and inhibiting topoisomerase enzyme 
activity during DNA replication. Although effective as an antitumor agent, DOX also 
causes a cumulative dose-dependent cardiotoxicity. In an attempt to address this adverse 
effect while maintaining efficacy, several synthetic modifications have been made to the 
original structure of DOX. GPX-150 and GPX-160, two novel synthetic DOX analogs, 
showed inhibitory effects against Top2α, indicating the analogs participate in forming the 
Drug-DNA-Top2α ternary complex similar to DOX. In in vitro antiproliferation assays, 
both analogs exhibited very promising anticancer activity against an array of cancer cell 
lines. In particular, GPX-160 showed similar IC50 values to DOX against human STS while 
lacking the structural properties associated with cardiotoxicity. Importantly, GPX-160 
appears to overcome DOX resistance due to P-gp mediated drug efflux. Moreover, the 
novel analogs both showed promising activity against human fibrosarcoma xenografts in 
immune-deficient mice, causing significant reductions in both tumor volume and tumor 
weight. 
Furthermore, pharmacokinetic studies showed that the analogs had biological stability 
that was markedly better than DOX, with drug half-lives in serum containing media that 
were 3-8 fold longer than DOX. Transport studies of GPX-150 and GPX-160 across Caco-
2 monolayers indicate the drugs cross the intestinal epithelial layer much more rapidly than 
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DOX, and suggest the drugs may have improved oral bioavailability. The drug metabolic 
turnover by HLM CYP450s, ALDH, and AKR show that GPX-150 and GPX-160 are less 
metabolically active than DOX. In particular, the lack of C-13 carbonyl in the analogs 
appears to prevent their metabolism by AKR, and the formation of the corresponding 
cardiotoxic alcohol metabolite, DOXol. CYP2C8 and CYP3A4 were found to be the most 
prevalent CYP isozymes for biotransformation of analogs. HPLC-MS-MS analysis 
determined dealkylation, demethylation, and deaglycosidation of DOX, GPX-150 and 
GPX-160 by CYP2C8 and CYP3A4. Further investigation of these metabolites need to be 
done to assess potential toxicities. The project was designed to discover and comprehend 
new generation of anthracyclines with improved potency without severe side-effects 
compared to that of the parent compound. The novel compounds with structural 
modifications of DOX certainly represents the groundbreaking development of anticancer 
agents for amplified chemotherapeutic treatment.
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APPENDIX A
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Fluorescence Profiles and Calibration Curves for DOX, GPX-150 and GPX-160 
DOX, GPX-150, and GPX-160 spectrofluorometric profiles were determined using a 
Varian Cary Eclipse fluorometer to identify the maximum excitation and emission 
wavelengths. These values are important for detection of the compounds in transport 
studies, and in assessing drug concentration. Fluorometry identified the maximal 
excitation/emission wavelengths to be: DOX (ex. 495 nm/em. 593 nm), GPX-150 (ex. 560 
nm/em. 630 nm) and GPX-160 (ex. 560 nm/em. 630 nm) as shown in Figure A1. The DOX 
excitation profile was similar to the reported literature (Paine, M. F.; Khalighi, M.; Fisher, 
J. M.; Shen, D. D.; Kunze, K. L.; Marsh, C. L.; Perkins, J. D.; Thummel, K. E. J. 
Pharmacol. Exp. Ther. 1997, 283 (3), 1552). The spectroscopic profiles for both GPX-150 
and GPX-160 showed identical wavelengths although GPX-160 contains a pyrrolino group 
at C-3’ position in the sugar moiety. This indicates that the absorption and radiation energy 
of both of the novel compounds share very similar Stokes fluorescence. 
Standard calibration curves were constructed using the optimal excitation and emission 
wavelengths and a series of drug concentrations (Figure A2). These calibration curves were 
later used for drug concentration and transport studies. To construct the calibration curves, 
 
Figure A1. Spectrofluorometric profiles of DOX, GPX-150, and GPX-160. The 
compounds were diluted to 2.5 µg/ml in DMEM. Excitation and emission profiles 
are shown in solid and dashed lines, respectively. 
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8 concentrations of test compounds were diluted in HBSS and the fluorescence measured 
on a BioTek Synergy MX multiwell plate reader. As can be seen in Figure A2, DOX was 
approximately 10-20 fold more fluorescent at its optimal excitation/emission conditions 
than GPX-150 or GPX-160. However, the data was linear for all of the compounds in the 
0 – 50 µM concentration range, allowing ready detection of low micromolar concentrations 
of drug. 
 
 
Figure A2. Calibration curves of DOX (495/593 nm), GPX-150, GPX-160 
(560/630 nm), and Lucifer yellow (428/536 nm). These calibration curves were used 
to examine drug transport across Caco-2 monolayers. 
 
L u c ife r  Y e llo w
C o n c e n t r a t io n  ( M )
F
lu
o
re
s
c
e
n
c
e
 (
A
U
)
0 .0 0 .5 1 .0 1 .5
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
Y = 32290*X + 18.35
R
2
 =  0 .9 9 9 3
D O X
C o n c e n t r a t io n  ( M )
F
lu
o
re
s
c
e
n
c
e
 (
A
U
)
0 1 0 2 0 3 0 4 0 5 0
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0 Y = 1015*X + 351.4
R
2
=  0 .9 9 6 1
G P X -1 5 0
C o n c e n t r a t io n  ( M )
F
lu
o
re
s
c
e
n
c
e
 (
A
U
)
0 5 1 0 1 5 2 0 2 5
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
Y = 134.5*X - 10.78
R
2
=  0 .9 9 6 9
G P X -1 6 0
C o n c e n t r a t io n  ( M )
F
lu
o
re
s
c
e
n
c
e
 (
A
U
)
0 5 1 0 1 5 2 0 2 5
0
5 0 0
1 0 0 0
1 5 0 0
Y = 51.88*X + 26.44
R
2
=  0 .9 9 4 6
91 
 
 
APPENDIX B 
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B1. Doxorubicin 
 
B2. GPX-150 
Figure B1. HLM metabolites of DOX after 30 min at 37°C. The mass spectra 
were collected at 4.1 minutes retention time from the HPLC chromatogram for 
DOX (M+H+) and the deglycosylated F1 fragment (top panel). The mass spectra 
for other metabolites (M1 – M6) was collected at 2.4-2.6 minutes retention time. 
See Chapter 3, Table 3 for comprehensive list of metabolites. 
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Figure B2. HLM metabolites of GPX-150 after 30 min at 37°C. The mass 
spectra were collected at 2.8 minutes retention time from the HPLC 
chromatogram to identify GPX-150 (M+H+) and the deglycosylated (F1) and 
deglycosylated/dehydrated (F2) products. The GPX-150 metabolites (M1-M5) 
were found at 2.8 minutes retention time. See Chapter 3, Table 3 for 
comprehensive list of metabolites. 
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B3. Schematic of DOX Metabolism 
 
 
B4. Schematic of GPX-150 Metabolism 
 
 
 
Figure B3. Based on LC/MS results, the predicted metabolites of DOX by aldo-
keto reductase (AKR) and CYP2C8 and CYP3A4 via human liver microsomes 
(HLMs). 
Figure B4. Based on LC/MS results, the predicted metabolites of GPX-150 by 
CYP2C8 and CYP3A4 via human liver microsomes (HLMs). 
